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ABSTRACT 
Lung cancer (specifically, non-small cell lung cancer; NSCLC) is the leading 
cause of cancer-related deaths in the United States. Poor response rates and survival with 
current treatments clearly indicate the urgent need to develop an effective means to treat 
NSCLC. Magnetic hyperthermia is a novel non-invasive approach for ablation of lung 
tumors, and is based on heat generation by magnetic materials, such as 
superparamagnetic iron oxide (SPIO) nanoparticles, when subjected to an alternating 
magnetic field. However, inadequate delivery of magnetic nanoparticles to tumor cells 
can result in sub-lethal temperature change and induce resistance. Additionally, non-
targeted delivery of these particles to the healthy tissues can result in toxicity. To 
overcome these problems, we used aerosol-based, tumor-targeted SPIO nanoparticles to 
induce highly selective hyperthermia for the treatment of lung cancer. 
Mechanistic study on the mode of cell kill by magnetic hyperthermia revealed that 
the extent and mechanism of MH-induced cell kill is dramatically altered with 
aggregation of SPIO nanoparticles. While well-dispersed SPIO nanoparticles induced 
apoptosis similar to that observed with conventional hyperthermia, sub-micron size 
aggregates, induced temperature-dependent autophagy through generation of oxidative 
stress. Micron size aggregates caused rapid membrane damage and acute cell kill, likely 
due to physical motion of the aggregates in alternating magnetic field. Overall, this work 
highlighted the potential for developing highly effective anticancer therapeutics through 
designed aggregation of SPIO nanoparticles.  
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Cancer stem cells (CSCs) are a sub-population of stem-like cells that are thought 
to be responsible for tumor drug resistance and relapse. We determined the susceptibility 
of CSCs to magnetic hyperthermia. Multiple assays for CSCs, including side population 
phenotype, aldehyde dehydrogenase expression, mammosphere formation and in vivo 
xenotransplantation, indicated that magnetic hyperthermia reduced or, in some cases, 
eliminated the CSC sub-population in treated cells. Magnetic hyperthermia demonstrated 
pleiotropic effects, inducing acute necrosis in some cells while stimulating reactive 
oxygen species generation and slower cell kill in others. These results suggest the 
potential for lower rates of tumor recurrence after magnetic hyperthermia compared to 
conventional cancer therapies.  
We then studied the effectiveness of inhalation delivery of tumor targeted SPIO 
nanoparticles for magnetic hyperthermia treatment of lung cancer. We developed EGFR-
targeted, inhalable SPIO nanoparticles for magnetic hyperthermia of NSCLC. EGFR 
targeting resulted in 50% higher concentration of iron oxide in the lungs 1 week post 
inhalation, when compared to non-targeted SPIO nanoparticles. Magnetic hyperthermia 
using targeted SPIO nanoparticles resulted in significant inhibition of in vivo tumor 
growth over a period of one month.  
Overall, this work demonstrates the potential for developing an effective 
anticancer treatment modality for the treatment of NSCLC, using targeted magnetic 
hyperthermia.  
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Chapter 1 
INTRODUCTION 
 
1.1. Non-Small Cell Lung Cancer (NSCLC) 
Although lung cancer accounts for only 15% of all newly-diagnosed cancers in 
the United States, it is the leading cause of cancer-related deaths in the United States 2. 
The American Cancer Society provides disturbing statistics for the year 2011, where 
there were 221,130 new cases and 156,940 estimated deaths from lung cancer 3,4. 
 The incidence of lung cancer is strongly correlated with cigarette smoking, with 
about 90% of lung cancers in men and 75-85% of lung cancers in women attributed to 
smoking 5. The risk of developing lung cancer in smokers is related to the age at which 
smoking started, time for which smoking continues and the number of cigarettes smoked. 
According to estimated projections, an absolutely radical reduction in smoking rates is 
required to achieve a significant reduction in the prevalence of lung cancer 6. However, it 
is worthwhile to note that approximately 10% of patients with lung cancer in the United 
States are found to be lifelong non-smokers. U.S. Environmental Protection Agency 
(2007) has estimated that secondhand smoke, i.e. the inhalation of tobacco smoke from 
other smokers, accounts for about 3000 deaths per year from lung cancer. Furthermore, it 
was recently reported that exposure to passive smoking during childhood increased the 
susceptibility to lung cancer in adulthood by 3.6 fold 7. Asbestos exposure increases the 
risk of lung cancer nine times and a combination of asbestos exposure with cigarette 
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smoking raises the risk to as much as 50 times. Lung diseases such as chronic obstructive 
pulmonary disease are associated with a greater risk (four to six times) for the 
development of lung cancer even when the effect of concomitant cigarette smoking is 
excluded. Other causes of lung cancer include air pollution (up to 1% lung cancer 
deaths), radon gas exposure (estimated 12% lung cancer mortalities) and genetic 
predisposition.  
There are two main types of lung cancer – small cell lung cancer (SCLC) and 
non-SCLC (NSCLC). NSCLC is more prevalent and accounts for 85% of all lung cancer 
cases. NSCLC can be further subdivided histologically into adenocarcinoma (40% of all 
cases), squamous cell carcinoma (25 – 30%), large cell carcinoma (10%) and not 
otherwise specified histology 8. The present 5-year survival rate for NSCLC (all stages 
combined) in the United States is roughly 15%. One reason for this is that the majority of 
patients are diagnosed at a late stage, locally-advanced or metastatic disease 9 as NSCLC 
has a tendency for early metastasis. The median survival time of a Stage 4 (metastatic) 
NSCLC patient is about 8 months. Therefore, for a vast majority of patients with 
NSCLC, primary care is principally palliative with most of them ultimately succumbing 
to the disease. 
Needless to say, the detection of lung cancer at an early stage is a critical 
requirement in order to improve the overall survival rate. For diagnosis, lung tumors are 
almost always first revealed by x-ray. In fact, the prevalent and historical use of x-ray 
positions this imaging methodology as the standard for detecting and characterizing 
tumors in the lung. Conventional clinical staging is most often performed with computed 
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tomography (CT) of the thorax and upper abdomen. However, in spite of being helpful in 
detecting early-stage tumors, CT is not specifically known to have any effect on reducing 
mortality rates 10. Various genetic alterations such as mutations in the tumor suppressor 
gene p53 11 and deletion or mutation of the retinoblastoma gene 12 have been reported, 
thus implicating these proteins as potential markers for the detection of lung cancer. Also, 
increased levels of angiogenic molecules like the vascular endothelial growth factor 
(VEGF) in serum and tumor tissue have been associated with poor prognosis in lung 
cancer patients 13,14. Gessner et al. 15 reported the breath-based detection of angiogenic 
markers (VEGF, bFGF, angiogenin) to specifically distinguish between early-stage 
NSCLC versus chronic obstructive pulmonary disease (COPD) patients and healthy 
volunteers. 
At present, surgical resection is the primary choice of treatment, followed by 
radiation and/or chemotherapy. Depending on the progression of the disease, surgical 
removal of large or singular tumor masses may involve removal of parts of a lobe (wedge 
and segment resection) if affected with very small tumors, one or more lobes 
(lobectomy), or an entire lung (pneumonectomy). Surgery is a highly invasive and 
expensive treatment option. Metastatic and locally advanced disease stages are not 
amenable to surgical resection, and importantly, a majority of patients who undergo 
surgery eventually experience relapse. A less invasive form of surgery called video 
assisted thoracotomy 16, utilizes a video camera to assist in visualizing and operating on 
the lung. Though the surgical incisions made are much smaller than those required for 
surgical resection, video assisted thoracotomy does not allow a complete lung 
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examination for identifying and removing lesions that remain undetected by preoperative 
chest x-ray. Besides, surgical intervention can cause lymphocytopenia 17, which is 
characterized by a decrease in the number of lymphocytes and is often associated with 
shorter survival times among patients with advanced stages of lung cancer.  
Radiotherapy uses high energy x-rays or other types of radiation to kill tumor 
cells. Depending on the source of radiation relative to the body, it can be divided into two 
types. External radiation therapy uses a machine outside the body to send radiation 
toward the cancer. Internal radiation therapy uses a radioactive substance sealed in 
needles, seeds, wires, or catheters that are placed directly into or near the cancer. 
Radiotherapy is a minimally invasive form of cancer treatment. However, it is associated 
with several adverse effects, which severely impact the quality of life.  
For chemotherapy of lung cancer, the most commonly used treatment regimens in 
the first line setting consist of a platinum containing agent (cisplatin or carboplatin), in 
combination with vinorelbine, gemcitabine, docetaxel, paclitaxel, or pemetrexed 18-24. 
These agents are given in a high dose for a limited duration. All of these combinations 
have proven to be relatively equivalent in response and toxicity, with most studies 
reporting response rates of 25 to 50%, with virtually no complete responses 25. Patients 
who relapse or become refractory to first line therapy are candidates for second line 
therapeutic regimens. Second line therapy usually consists of sequential use of single 
chemotherapeutic agents such as docetaxel or experimental therapy 26.  
Recently, there is increased interest in investigating the effect of adding a novel 
biologic drug or a “targeted agent” in combination with platinum-based chemotherapy. 
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These agents are proven to have reduced toxicity compared to standard cytotoxic 
chemotherapy, mainly because of the specificity of the mode of action of these drugs. For 
instance, the addition of a monoclonal antibody (bevacizumab) that targets VEGF to a 
platinum based chemotherapy regimen has resulted in enhanced delivery of the 
chemotherapeutic drugs to the tumor site due to alteration in the tumor vasculature 27, 
causing a statistically significant improvement in progression-free survival and overall 
survival 28. On the other hand, EGFR overexpression has been associated with poor 
prognosis in 40% to 80% of NSCLC patients 29. However, treatment with EGFR tyrosine 
kinase inhibitors, gefitinib and erlotinib showed a dramatic antitumor activity in only a 
minority of patients harboring mutations in the tyrosine kinase domain of EGFR 30,31.  
Other treatment options include laser surgery, cryosurgery, electrocautery, 
radiofrequency ablation and photodynamic therapy. Laser surgery allows surgeons to 
remove small amounts of lung tissue, and it is proving useful for improving symptoms in 
stage II and IIIA patients and in treating cancers that have spread to, and are obstructing, 
the throat. Cryosurgery or cryotherapy uses a chilled probe to freeze and destroy the 
tumor cells on contact. Electric cauterization or thermal ablation, which uses electricity to 
produce heat that destroys tissue, is also under investigation as a treatment for early-stage 
disease. Radiofrequency ablation is a non-surgical technique that uses an x-ray guided 
electrode to deliver heat to tissues. Since this technique spares nearby normal tissues, 
patients tend to have minimal side effects. More research is needed to confirm the benefit 
of radiofrequency ablation over other, non-surgical treatment options. Recently FDA has 
approved photodynamic therapy (PDT) for the treatment of both early and late stage lung 
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cancer 32-35. Though PDT is non-invasive and has fewer side effects, it has some 
drawbacks including the need for the tumor to be accessible to the inserted bronchoscope 
and the limited depth of penetration of the laser light, which renders it inefficient for 
treating larger tumors. Poor response rates and survival with current treatments clearly 
indicate the immediate need to develop an effective means to treat NSCLC.  
 
1.2. Hyperthermia as an Anticancer Therapy 
Hyperthermia, as a medical intervention, is defined as the heating of an organ or a 
tissue to a temperature between 41ºC and 46ºC to decelerate growth and sensitize, 
damage or otherwise destroy tissue 36,37. A non-invasive approach for tumor ablation, 
hyperthermia is associated with fewer side effects compared to chemotherapy and 
radiotherapy, and is highly effective in eradicating localized or deep-seated tumors. In 
clinical studies, diverse hyperthermic approaches have been used, including 
local/interstitial and regional hyperthermia, whole body hyperthermia 38,39 and 
hyperthermic perfusion techniques such as hyperthermic isolated limb perfusion 40-42 and 
hyperthermic peritoneal perfusion 43,44. Several clinical studies have shown that 
hyperthermia, often in combination with radiotherapy, surgery and/or chemotherapy, 
results in improved tumor response and survival rates 45-50. 
There are several molecular effectors of hyperthermia in the treated cells. The cell 
membrane and cytoskeleton undergo changes in fluidity and membrane potential, 
resulting in the impairment of transmembrane transport and loss of cellular integrity. In 
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addition, there is impairment of protein synthesis, denaturation of proteins, and 
aggregation of proteins in the nuclear matrix. Hyperthermia also results in DNA damage, 
inhibition of repair enzymes and impaired DNA synthesis. Most of these alterations are 
fatal and result in the induction of apoptosis 51,52. Tumor cells upregulate stress proteins 
such as the heat shock proteins (HSP) to counter hyperthermia 53,54. Elevated HSP 
expression can impart increased resistance to subsequent chemotherapy and radiation 
treatments, thereby promoting tumor recurrence. However, HSP-induced heat resistance 
can be overcome by optimizing hyperthermia protocols. Monitoring of cellular HSP 
expression can be employed to develop a treatment strategy that is optimized for tumor 
ablation without inducing resistance.  
 
1.3. Magnetic Hyperthermia Using Super-Paramagnetic Iron 
Oxide (SPIO) Nanoparticles 
Several techniques have been utilized for localized heating of tumors including 
microwave radiation, ultrasound, laser and electromagnetic radiation. However, the most 
commonly used heating method in clinical settings is capacitive heating 55,56. Capacitive 
heating is a form of electric heating where an electrically non-conducting material 
interacts with a conducting surface leading to a loss of internal energy in the conducting 
surface and a subsequent rise in temperature in the adjacent, non-conducting material 57. 
Radiofrequency electric field is often used to produce capacitive heating. However the 
technique has been challenging in clinical settings due to the requirements of precise 
positioning of the electrodes in the tumor, size of the tumor and its depth in the body 56. 
  8 
Thus, from the clinical point of view, it is more desirable to use a simple heat mediator, a 
substance that mediates heat in the bodily tissue to be dispersed throughout the regions of 
interest. Magnetic nanoparticles have been examined as heat mediators because of their 
chemical stability, biocompatibility, and non-carcinogenicity.  
The technique of using of superparamagnetic nanoparticles subjected to an 
alternating magnetic field to generate heat is called magnetic hyperthermia 58. The first 
report on the use of magnetic particles for tumor heating by exposure to an alternating 
magnetic field (AMF) dates back to 1957 59. The advantage of magnetic hyperthermia is 
that the heating temperature and area can be well controlled by adjusting particle size, 
shape, suspending media and the properties of the alternating magnetic field 60. There are 
several magnetic materials that can be used for inducing magnetic hyperthermia, but most 
studies have focused on magnetic iron oxides, Fe3O4 (magnetite) 61,62 and γ–Fe2O3 
(maghemite) 63,64, which have been proved to be well tolerated in clinical studies. In fact, 
magnetite is approved for human use as a diagnostic agent, and therefore has a good 
anticipated safety profile 65 
 
1.4. Basic Concepts of Magnetism  
The basic principle of magnetism is that magnetic induction (B), which is the 
overall magnetic response of the individual atomic moments of a magnetic material 
located in a magnetic field of strength, H can be denoted by  = μ + 	, where 0µ is 
the permeability of the free space and M is the magnetization of the material. Depending 
on the type of magnetic material, different types of magnetic behavior is observed 
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including paramagnetism, diamagnetism, ferromagnetism, antiferromagnetism, 
ferrimagnetism and superparamagnetism.  
Paramagnetism and diamagnetism exhibit magnetic moments only in the presence 
of an externally applied magnetic field. Paramagnetic materials have unpaired electrons 
which are free to align their magnetic moment in any direction. In the presence of an 
external magnetic field these magnetic moments tend to align in the direction of the field, 
thus reinforcing it. On the other hand, diamagnetism appears in all materials and is 
characterized by the tendency of a material to oppose an applied magnetic field thereby 
weakening it. In contrast to paramagnetic materials, a permanent magnet possesses its 
magnetic moment in the absence of an external magnetic field and may be ferromagnetic, 
antiferromagnetic or ferrimagnetic, depending on the net alignment of the magnetic 
moments. In these materials, the alignment only occurs at temperatures below a certain 
critical temperature, called the Curie temperature (for ferromagnets and ferrimagnets) or 
the Néel temperature (for antiferromagnets). Above the critical temperature, the unique 
magnetic properties are lost. 
Superparamagnetism is a form of magnetism where, unlike ferromagnetic or 
ferrimagnetic substances, paramagnetic behavior is observed even at temperatures below 
the Curie or the Néel temperature. Superparamagnetic nanoparticles are single-domain 
magnetic materials composed of very small crystallites. Owing to their small size, 
thermal fluctuations can change the direction of magnetization of the entire crystal. This 
unique property makes superparamagnetic particles, attractive candidates for clinical 
heating applications 66.  
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1.5. Heating Mechanism of Magnetic Particles  
 Magnetic materials can exhibit three different heating mechanisms when placed 
in an alternating field: generation of eddy currents in a bulk magnetic material, hysteresis 
losses in a bulk magnetic material, and relaxation losses in a single domain magnetic 
material 60,67. Due to the small size of superparamagnetic particles and the low frequency 
of the AMF, inductive heating due to eddy current is negligible 67. While polydispersity 
of superparamagnetic substances can result in a small remanence, monodisperse particles 
(<100 nm) fall in the single domain regime and have no hysteresis loop in a measurement 
of the induced magnetic field as a function of the applied magnetic field. Hence, the usual 
mechanism of heating of these particles arises from energy losses due to a combination of 
the two relaxation processes – Brownian relaxation and/or Néel relaxation 67,68. In small 
particles (about 5 – 15 nm) or at a high frequency of AMF, Néel relaxation predominates 
where the particles remain stationary but magnetic moment rotates away from the 
original easy axis of the crystal towards the external field in order to orientate the 
moment across an effective anisotropy barrier within each particle. In contrast, Brownian 
relaxation is the primary source of heat generation in larger particles (more than 20 nm) 
or at a lower frequency of AMF. Upon application of an external magnetic field, the 
particle rotates against the viscous friction of the fluid towards the field with its moment 
locked along the crystal axis.  
Each of the relaxation modes are characterized by the respective time constants. 
The Néel time constant, Nτ , is independent of the viscosity of the surrounding medium 
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and at any given temperature T, it is primarily determined by the radius of the magnetic 
core RM 68,69. Mathematically,   
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constant (3 X 104), kB is Boltzmann’s constant (1.38 X 10-23) and VM is the magnetic 
volume given by  =




. 
In contrast, Brownian time constant Bτ , depends on the viscosity of the surrounding fluid 
η and the hydrodynamic radius of the magnetic substance RH and is given by, 
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thickness of the sorption layer on the particles. Since the two modes of relaxation occur 
in parallel, the effective relaxation time, τ , is given by 
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The quantitative basis of heating superparamagnetic particles by an AMF of 
strength H, is given by 70: 
% = &'()
2)

1 + 2)
	(
 
Where P is the volumetric power dissipation or the specific absorption rate, which 
is defined as the amount of heat released per unit volume of the material per unit time,  
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0 4 10µ pi= ×  (TmA-1) is the permeability of free space, f is the frequency (Hz), and 0χ  is 
the actual susceptibility, which can be calculated by a complex Langevin equation 70. The 
resulting temperature increase for these particles depends on the duration of heating Δ+, 
and the specific heat capacity of the sample c and is given by Δ = %Δ+/-. 
 
1.6. Murine models in lung cancer therapy research 
Murine models of lung cancer serve as an important tool for understanding the 
molecular pathways involved in the development of lung cancer and allow for the 
development and validation of novel therapeutic approaches as well as identification of 
markers for early diagnosis. To achieve these goals, it is essential for the mouse lung 
tumor models to closely mimic the different lung tumor types with respect to both critical 
genetic alterations and tumor cell characteristics. However, for translation therapy, it is 
also essential for the models to be quantifiable in terms of alteration of tumor growth 
after administration of the therapeutics. Every tumor model has its own set of merits and 
demerits. While some models facilitate easy measurement at the expense of similarity 
with actual human lung tumors, other models provide remarkable resemblance to the host 
tumors but are extremely difficult to monitor. However, the most popular models are 
those that try to achieve a balance between the two.  
Xenograft models have been extensively used for preclinical testing of lung 
cancer therapeutics 71. The most prevalent model is the subcutaneous xenograft model, 
which involves subcutaneous injection of human lung cancer cell lines into 
immunodeficient mice. This model is widely popular due to its simplistic nature and has 
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several advantages including easy administration of cells to induce tumors without the 
necessity of anesthesia and also convenient monitoring of the tumors by direct 
measurement of tumor dimensions, thereby allowing longitudinal follow up. However the 
primary drawback of this model is the discrepancy between xenograft origin and host 
microenvironment 72. As a consequence of these discrepancies, tumor response to 
cytotoxic agents, radiation therapy 73 and novel anticancer agents are greatly affected. In 
addition, these differences might be critical in NSCLC, where hypoxia and 
neovascularization play a major role in tumor progression 74. Finally, only a few 
subcutaneous tumor models disseminate and progress to the metastatic stage, thus 
rendering this model useless in studying metastasis, a major cause of lung cancer 
mortalities. 
Orthotopic models of lung cancer have been developed over the last two decades. 
These models can utilize the benefits of organ specificity and tumor microenvironment of 
lung tumors that mimic the clinical situation and still allow longitudinal follow up. 
Several techniques are prevalent for the transplantation of human lung tumor cells in their 
natural pulmonary environment. Intrabronchial 75-77 and intrapleural administration 78,79 
of lung cancer cell lines resulted in pleural, locally advanced, or multiple synchronous 
tumors. Tracheal instillation of lung cancer cells into mice has also been utilized as a 
non-invasive route of delivery of cells to the lungs. Intravenous 80 injections of certain 
lung cancer cells like A549 also lead to experimental metastasis and tumor formation in 
the lungs 81. Transfection of fluorescent proteins or luciferase enzyme in the lung cancer 
cells allows for fluorescence or luminescence-based imaging of tumor growth 82. While 
  14 
these models are useful in studying therapeutic efficacy of cancer treatments, they are not 
particularly suitable for studying chemoprevention or identification of lung cancer 
biomarkers. In addition, these models are studied in immumo-compromised rodents, and 
thus the role of host immune system on tumor development is overlooked. 
A modification of the orthotopic model involves surgical implantation of NSCLC 
fragment into the lung of immunodeficient mice via thoracotomy 83-85. Tumor fragments 
from fresh primary tumors or subcutaneous NSCLC xenografts were inserted into the 
lung parenchyma, on the visceral pleura, or on the parietal pleura. Mortality rates due to 
the procedure itself were around 10%, and the engraftment rates ranged between 60 and 
100%. This technique requires specialized laboratory techniques and experienced 
professionals to perform the surgical intervention. Despite encouraging preliminary 
results 86, lack of systemic metastasis and technically difficulty in performing the 
procedure have discouraged the widespread use of this model for preclinical NSCLC 
research.  
Carcinogen-induced lung tumor models utilize chemical carcinogens for the 
induction of tumors. This model is very reproducible and almost invariably results in 
pulmonary adenoma and adenocarcinomas 87,88. Spontaneous lung cancer develops in 
approximately 3% of wild mice, however, the susceptibility to and incidence of 
spontaneous lung tumors vary largely between strains 89. Strains that have a high 
spontaneous lung tumor incidence are also very responsive to chemical induction of lung 
tumors, for example, exposure to cigarette smoke, tar, or chemically pure carcinogens 87. 
A/J and SWR mice are among the most sensitive strains for spontaneous tumor 
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development, while others range from being somewhat sensitive (O20 and BALB/c) to 
more resistant (CBA and C3H) to almost complete resistant (C57BL/6 and DBA). 
Several quantitative carcinogenicity assays 87,90,91 and chemopreventive drug screening 
systems 92,93 have been developed using this model. A wide variety of chemicals have 
been used for lung tumorigenesis including urethanes, metals, aflatoxins, and constituents 
of tobacco smoke such as polyaromatic hydrocarbons and nitrosamines 87,94-96. One of the 
primary drawbacks of this model is the difficulty in monitoring tumor development and 
progression, thereby posing a challenge in performing chronological studies to monitor 
the efficacy of therapeutic agents. 
Introduction of genetic lesions found in human lung cancer into the mouse 
germline or pulmonary tissue has resulted in the development of murine lung tumors. 
These genetically engineered mouse models (GEMM) bear close resemblance the human 
lung tumors and serve as an important tool for studying NSCLC in mice. These animals 
are usually p53 mutated, favoring genetic instability and tumor formation. Development 
of lung tumors driven by oncogenic activation of K-Ras 97, EGFR 98, BRAF 99, PI3K 100 
or the presence of EML4-ALK fusion oncogene 101 have been reported. Compared to other 
murine lung tumor models, GEMM have the advantage of taking immune response into 
account. Although GEMM mimics human lung cancer better than other models, it is still 
far from clinical situation. Mutations of a few oncogenes or tumor suppressors are not 
representative of the multistep progression of lung cancer occurring in humans. 
Furthermore, GEMM models result in hundreds of primary NSCLC in the same period of 
time, which are difficult to follow and to quantify during preclinical testing and through 
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non-invasive imaging. Despite these drawbacks, recent studies have reported that GEMM 
may be of interest in evaluating the efficacy of common NSCLC treatments 102. 
The use of murine models of lung cancer for studying therapeutic efficacy 
necessitates sophisticated non-invasive tools to follow tumor development and response 
to therapy 103. It is essential to measure tumor size as a function of time and existing 
techniques such as positron emission tomography-computed tomography or magnetic 
resonance imaging have been adapted for use on small animals 100,104. However, these 
techniques are less suitable for high throughput studies since they are expensive and time 
consuming. Other sensitive and reproducible techniques for monitoring in vivo tumor 
growth are based on fluorescence and bioluminescence imaging 105,106. Expression of 
fluorescent proteins can be coupled to oncogenes in transgenic mouse models or 
transfected to lung tumor cells in xenograft models, thereby facilitating fluorescent 
imaging of tumor growth. Similarly, transgenic expression of luciferase or its transfection 
into the tumor cells forming xenografts allows monitoring and quantification of tumor 
volume by bioluminescence imaging. Feasible imaging and quantitation techniques and 
expression of the gene of interest are thus important criteria for the selection of a suitable 
lung tumor model. 
In our studies, we used an experimental A549 lung colonization model for the 
development of orthotopic lung tumor xenografts. A549 is a human lung adenocarcinoma 
cell line, which was first established from an explanted tumor of a 58 year old Caucasian 
male 107. Several reports suggest that A549 cells overexpress EGFR, which makes it an 
attractive candidate for studying the effectiveness of EGFR targeted drug delivery. A549-
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luc-C8 Bioware® Cell Line (Caliper Lifesciences) is a luciferase expressing cell line 
derived from A549 human lung squamous carcinoma cells by stable transfection of the 
North American Firefly Luciferase gene expressed from the CMV promoter. Luciferase 
expression in these cells can facilitate the visualization of tumor cells in live animals 
using bioluminescence imaging. Intravenous injection of A549-luc-C8 cells leads to 
colonization of the lungs by these cells. The cells lodged in the lung alveolar epithelium 
start multiplying, and the progression of tumor growth can be monitored by 
bioluminescence imaging after an intraperitoneal injection of the chemical substrate 
luciferin. Lung bioluminescence increases with time after tumor cell injection as 
illustrated in Figure 1.1. 
 
 
 
 
 
 
Figure 1.1 Experimental metastatic lung tumor development after A549-Luc cells 
injection. The luminescence in the lung (tumor) and the radiance between weeks 3 to 
6 after tumor cell injection. The absolute value of the radiance is also shown. 
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1.7. Inhalation drug delivery 
Inhalation drug delivery is an attractive option for the treatment of lung diseases. 
In contrast to systemic delivery, pulmonary delivery is advantageous due to the 
noninvasive means of delivering high drug concentrations directly to the disease site, 
which minimizes risk of systemic side-effects while providing rapid onset of clinical 
response. Additionally, this route bypasses first-pass metabolism in the liver and is also 
capable of achieving similar or superior therapeutic effect at a fraction of the systemic 
dose 108-111. It has been widely accepted as the optimal route of administration of first-line 
therapy for lung disorders like asthma, chronic obstructive pulmonary disease, cystic 
fibrosis, and chronic bronchitis 112. It has also been considered for gene therapy and 
smoking cessation. An often overlooked and yet promising use of inhalation therapy is 
for the treatment of lung cancer. While inhaled therapeutics can potentially reach the 
tumor cells, it is essential to understand the path traversed by these particles in order to 
develop an optimal therapeutic system.  
Human respiratory tract is considered to have two anatomical regions (upper and 
lower). The upper respiratory tract comprises of the nasal/oral cavity, larynx and 
pharynx. The lower respiratory tract includes the trachea, bronchi, bronchioles, and 
alveoli. The trachea follows the larynx as inhaled air moves into the lung. After the 
trachea, the left and right bronchi are encountered. This is the first of many bifurcations 
of the respiratory tract, which is repeated until the alveolar ducts are reached. A complex 
branching pattern arises from these divisions, which in turn affects the mechanism, site of 
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deposition and dose of therapeutics delivered to the lungs. For most therapeutics, 
suboptimal dose delivery or uneven distribution in the lungs can compromise the 
effectiveness of therapy.  
 Aerosol particle size is one of the most important variables affecting the 
deposition dose and the distribution of drug in the lung 113-115. Fine aerosols are 
distributed on peripheral airways but deposit less therapeutics per unit surface area (due 
to their smaller mass) than larger particle aerosols which deposit more drug per unit 
surface area (due to higher mass per particle), but on the larger, more central airways 116. 
Most therapeutic aerosols are seldom monodisperse. They consist of a wide range of 
particle sizes, which is often determined from cascade impaction studies. The particle 
size follows log-normal distribution and can be quantified by plotting the log of particle 
diameters against particle number, surface area or volume (mass) on a linear or 
probability scale and expressed as absolute values or cumulative percentage. There are 
several ways of defining aerosol particle size. Mass median diameter of an aerosol refers 
to the particle diameter corresponding to the median of the mass distribution, i.e. it has 
50% of the aerosol mass residing above and 50% of its mass below it. The aerodynamic 
diameter of particles is often defined as the diameter of a sphere of unit density that has 
the same settling velocity as the particle of interest regardless of its shape or density. The 
particle aerodynamic diameter (da) can be calculated as ./ 	= 	 .012 2⁄ 	  where, 
dh is mean hydrodynamic diameter determined from light scattering technique, ρ0 is the 
standard particle density (1000 kg/m3) and ρ is the density of the particle of interest. The 
most commonly used measure of aerosol size is its mean median aerodynamic diameter 
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(MMAD), which is read from the cumulative distribution curve at the 50% point. 
Geometric standard deviation (GSD) is a measure of the variability of particle diameters 
within the aerosol and is calculated from the ratio of the MMAD to the particle diameter 
at 16% point on the cumulative distribution curve. For a log-normal distribution, the GSD 
is the same for number, surface area or mass distributions. A GSD of 1 indicates a 
monodisperse aerosol, while a GSD of >1.2 indicates that the aerosol is heterodisperse. 
The aerodynamic size of particles determines the force during the motion of 
inhaled particles. In the upper airways like the trachea and bronchi, the inertial force of 
larger particles predominate thereby causing the particles to escape the streamlined flow 
and collide with the airway wall and deposit 117. Most particles >10 µm are deposited in 
the oropharyngeal region due to inertial impaction especially when the drug is inhaled 
from devices requiring a high inspiratory flow rate (like dry powder inhalers) or when the 
drug is dispensed from a device at a high forward velocity (like metered dose inhalers) 
118
. Ciliary clearance mechanisms transport these larger particles into the oesophagus, 
where they are subsequently swallowed and contribute minimally, if at all, to the 
therapeutic response. After the larger particles are cleared in the upper airways, the 
slightly smaller particles are filtered out of the airstream in the middle airways like the 
bronchioles and the terminal bronchioles, primarily due to gravitational sedimentation 117. 
Finally, very small particles (less than 0.5 µm) are carried to the alveolar region by the 
airstream where Brownian diffusion is the predominant mechanism of deposition and 
distribution 119. While larger particles (>6 µm in humans) are easily cleared from the 
tracheal region by muco-ciliary clearance 120, very small particles (<1 µm for humans) 
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are often carried out of the lungs during exhalation 121. Thus, the highest alveolar 
deposition in humans is achieved by aerosols having 1 – 5 µm aerodynamic diameter. 
 The lung size in small rodents like mice is much smaller than that in humans and 
the diameters of their airways scale proportionately. Additionally, mice are obligate nose 
breathers, which pose serious challenge in the design of an appropriate inhalation system 
that allows for high lung deposition of nanoparticles. An MMAD of 1 µm has been 
shown to result in the highest concentration of the therapeutic agents in all lobes of 
mouse lungs 122. This size yields a deposition fraction (percent of mass deposited in the 
lungs to total mass inhaled) of about 10% 123,124. However, pre-acclimatization of the 
animals to the inhalation chambers and prolonged aerosol exposure can prevent undue 
stress and uneven breathing pattern, thereby increasing lung deposition. Premixing air 
with carbon dioxide leads to deeper inhalation by the test animals, which in turn can also 
increase mass delivered into mouse lungs. Other approaches like magnetic deposition of 
SPIO nanoparticles into the lungs 124 or microspraying technique 125 can also enhance the 
deposition fraction several folds. 
 
1.8. Tumor targeted drug delivery 
An important goal in drug delivery is to enhance the availability of therapeutics at 
its site of action while minimizing off-target exposure and deposition. One of the 
techniques for achieving this purpose is by functionalizing nanoparticle surface with cell 
or organ specific ligands. Several targeting moieties like antibody 126,127, antigen 128,129, 
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aptamer 130, lectin 131,132, protein/peptide 133,134 and enzyme 135 have been investigated to 
target cancer cells. Selection of targeting ligands is almost always based on presence or 
overexpression of the target in tumors of interest.  
Several receptors are overexpressed in lung tumors including folate receptor 136, 
µ-opioid receptor 137, G-protein coupled receptors 138, Insulin-like growth factor-1 
receptor 139 and epidermal growth factor receptor (EGFR). Interestingly, EGFR 
overexpression has been observed in as many as 70% of NSCLC patients 140-142. In these 
patients, EGFR overexpression is more frequent in epithelial sites within tumors than 
those in sites adjacent to and distant from tumors. This suggests that SPIO nanoparticles 
targeted to EGFR will be specific to tumor cells and will not affect the neighboring 
healthy cells. Monoclonal antibodies against EGFR (cetuximab) and EGFR tyrosine 
kinase inhibitors are clinically used for lung cancer. Thus, EGFR is an attractive target in 
lung cancer.  
In our studies, we will use a previously reported 11-residue peptide ligand 
(YHWYGYTPQNVI) for targeting EGFR. This peptide binds specifically and efficiently 
to EGFR (dissociation constant of ~20 nM), but has much lower mitogenic activity than 
EGF 143. By combining receptor targeting with magnetic activation, superior tumor 
selectivity is expected. 
 
Although magnetic hyperthermia is a highly promising approach for tumor 
ablation, currently available techniques for inducing magnetic hyperthermia fail to kill 
the tumor cells effectively. Inadequate delivery of magnetic nanoparticles to tumor cells 
  23 
results in sub-lethal temperature change. This can induce resistance in tumor cells, 
because of induction of heat shock proteins (HSPs). Additionally, non-targeted delivery 
of these particles to healthy tissues can result in toxicity. To overcome these problems, 
we propose to use aerosol-based, tumor-targeted SPIO nanoparticles to induce highly 
selective hyperthermia (Figure 1.2). Aerosolized SPIO particles will be directed to the 
periphery of the lung by controlling the aerodynamic size of SPIO aggregates. Once the 
aggregates come in contact with the lung fluids, they will disaggregate to release the 
individual SPIO nanoparticles. The presence of tumor targeting ligand on the surface will 
enable SPIO nanoparticles to bind to a greater extent to the tumor cells. SPIO particles 
that are not bound will undergo muco-ciliary clearance from the lung. Hyperthermia will 
be induced when the concentration of SPIO particles is the highest in tumors and lowest 
in normal tissue, thereby preventing toxicity to healthy cells. 
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Figure 1.2 Proposed mode of tumor cell kill with targeted magnetic hyperthermia. 
An inhalable formulation of SPIO nanoparticles conjugated to EGFR targeting ligand 
will be used. The presence of targeting ligand will enable these particles to bind 
specifically to the tumor cells. Particles that are not bound are expected to be cleared 
by muco-ciliary clearance, preventing toxicity to healthy cells. The surfactants in the 
lung will help disaggregate the formulation into individual targeted SPIO 
nanoparticles, which are then free to bind to tumor cells. After the unbound particles 
are cleared from the lung, magnetic field will be applied resulting in heat generation 
and subsequent tumor cell death. 
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1.9. Hypothesis and Specific Aims 
There are several challenges in developing an effective inhalable lung cancer 
therapy. The restrictions in the deliverable dose to the lungs warrants a study to 
determine the most effective mechanism of cell kill. Additionally, lung cancer is 
notorious for tumor recurrence, where the primary culprit is believed to be cancer stem 
cells, which are a sub-population of stem-like cells. Thus, it is essential for an effective 
treatment option to successfully eliminate cancer stem cells. Finally, the major challenge 
in cancer therapy is the need to specifically target and eliminate malignant cells. The 
state-of-the-art methods to realize tumor specificity are based on targeting tumor-specific 
receptors or the use of external stimuli. Receptor targeting provides cell specificity within 
a specific tissue but suffers from nonspecific systemic distribution. Targeting approaches 
that utilize activating stimuli such as magnetic hyperthermia provide organ specificity but 
lack cell specificity in that healthy and malignant cells in a given tissue are equally 
affected. This is a particular problem in most peripheral lung cancers, because malignant 
cells are located in the midst of healthy tissue essential for life sustaining respiration. A 
multi-modal targeting approach involving an external stimulus in conjunction with 
receptor-based targeting can potentially combine the advantages of the two approaches to 
specifically target the malignant cells. We hypothesize that inhalable SPIO nanoparticles 
surface-functionalized with EGFR targeting ligand, when exposed to an appropriate 
magnetic field, will enable highly efficient and specific tumor cell death by hyperthermia. 
We will test this hypothesis by pursuing the following specific aims:  
Specific Aim #1: Determine the mechanism of cell kill by magnetic hyperthermia. 
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Specific Aim #2: Evaluate the susceptibility of cancer stem cells to magnetic 
hyperthermia. 
Specific Aim #3: Determine the in vivo anticancer efficacy of inhaled EGFR-
targeted SPIO nanoparticles 
In the following chapters, each aim is addressed. Chapter 2 describes the results 
of a mechanistic study performed to determine the mode of cell kill by magnetic 
hyperthermia. SPIO nanoparticles having different extent of aggregation from well-
dispersed, non-aggregated nanoparticles to sub-micron size aggregates to larger micron 
sized aggregates were studied. In vitro studies were performed to analyze the extent and 
mechanism of cell kill by the different particles. The in vitro results were verified in an in 
vivo mouse model of subcutaneous A549 lung tumor xenograft. This work highlights the 
potential for developing highly effective anticancer therapeutics through the modification 
of the state of aggregation of SPIO nanoparticles. Chapter 3 is focused on studying the 
effects of magnetic hyperthermia on cancer stem cells. Multiple assays for cancer stem 
cells, including side population phenotype, aldehyde dehydrogenase expression, 
mammosphere formation and in vivo xenotransplantation, were performed to determine 
the susceptibility of cancer stem cells to magnetic hyperthermia. This study helped in 
understanding the long-term effects of magnetic hyperthermia as an anti-cancer treatment 
modality. In the final study, we developed EGFR-targeted, inhalable SPIO nanoparticles 
for magnetic hyperthermia of NSCLC. The effect of EGFR targeting on in vivo lung 
tumor retention and the resulting therapeutic efficacy has been discussed in Chapter 4.        
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ENHANCING THERAPEUTIC EFFICACY THROUGH DESIGNED 
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2.1. Introduction 
Nano drug delivery systems are of considerable interest in cancer therapy because 
of their ability to accumulate passively in tumors 144-146. A key area of research is the 
effect of size of the delivery system on therapeutic effectiveness 147-149. Several reports 
suggest that the optimal size of nanoparticles for tumor therapy is around 100 nm 146. 
However, the presence of proteins can lead to aggregation of nanoparticles in biological 
environment 150-153. For example, depending on the surface properties, nanoparticles can 
form sub-micron to micron size aggregates in the presence of serum proteins 154,155. The 
effect of aggregation on the therapeutic performance of nanoparticles has not been 
previously investigated.  
In our studies, we examined the consequence of aggregation on 
superparamagnetic iron oxide (SPIO) nanoparticle-induced magnetic hyperthermia (MH). 
Superparamagnetic materials generate heat when placed in alternating magnetic field 
156,157
. Depending on the size of the material, heat is generated through either Néel or 
Brownian relaxation or a combination of the two 67,68. Heat generated and the associated 
temperature change from such relaxation phenomena dissipates over short distances due 
to the high thermal conductivity of water and can therefore be used for highly focused 
heating 58,158. This concept is utilized in MH, where an external magnetic field is applied 
to SPIO nanoparticles trapped in tumor tissue, resulting in local heating and tumor cell 
kill58.  
Our results show that the extent and mechanism of MH-induced cell kill is 
dramatically altered with aggregation of SPIO nanoparticles. Aggregated nanoparticles 
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were much more effective in killing tumor cells than well-dispersed, non-aggregated 
nanoparticles, and micron size aggregates were more effective than sub-micron size 
aggregates. Interestingly, cell kill induced by micron size aggregates was largely 
temperature-independent, and was characterized by acute membrane damage. This is the 
first report to demonstrate improvements in therapeutic efficacy achieved through 
designed aggregation of nanoparticles. 
2.2. Materials and Methods 
2.2.1. Materials 
Ferrous chloride tetrahydrate, ferric chloride hexahydrate, myristic acid, Pluronic 
F127, ascorbic acid, potassium hydroxide, 1,10-phenanthroline and sodium acetate were 
purchased from Sigma (St. Louis, MO). Penicillin/streptomycin, fetal bovine serum, 
Dulbecco’s phosphate buffered saline, F-12K (Kaighn’s modification) and trypsin-EDTA 
solution were obtained from Invitrogen Corporation (Carlsbad, CA). Cytotox 96® non-
radioactive cytotoxicity assay and CellTiter 96® AQueous one solution cell proliferation 
assay kit were purchased from Promega (Madison, WI). The commercial SPIO 
nanoparticles (Nanomag®) were purchased from Micromod Partikeltechnologie GmbH 
(Rostock, Germany). For Western blotting, antibody against HSP70 was from Enzo Life 
Sciences (Farmingdale, NY), anti-GAPDH-HRP and anti-β-actin-HRP were from Sigma, 
anti-PARP1, anti-cleaved PARP1, anti-LC3B and HRP-linked anti-rabbit and anti-mouse 
IgG were from Cell Signaling Technology (Danvers, MA). 
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2.2.2. Methods 
2.2.2.1. Synthesis of SPIO nano and micro aggregates 
 SPIO nanoparticles were synthesized by condensation of 0.82 g ferric chloride 
hexahydrate and 0.33 g ferrous chloride tetrahydrate dissolved in 30 ml of degassed and 
nitrogen-purged water with 3 ml of 5 M ammonium hydroxide. The reaction was allowed 
to continue for 30 minutes under magnetic stirring (200 gauss magnetic stir bar, 1600 
rpm) and nitrogen gas bubbling through the reaction mixture. Iron oxide formed was 
washed three times with 30 ml of nitrogen-purged water, followed my magnetic 
separation and heating on a hot (80˚C) oil bath. About 100 mg of myristic acid was added 
to the heated mixture, which was stirred for another 30 min at 1600 rpm using a 200 
gauss magnetic stir bar. Excess myristic acid was removed by two washes with acetone, 
followed by two washes with water to remove excess acetone. Each wash was followed 
by magnetic separation of nanoparticles. The myristic acid-coated particles were then 
suspended in 30 ml water using a water-bath sonicator and 100 mg of pluronic F127 was 
added and stirred overnight. The final dispersion was fractionated by centrifugation at 
800 g for 6 minutes. The supernatant contained nano aggregates. The pellet was dispersed 
in 15 ml of water and 20 mg pluronic F127 by sonication for 1 hour and was comprised 
of micro aggregates. 
 Coumarin-6 labeled SPIO nanoparticles were synthesized by incorporating 
coumarin-6 into the fatty acid layer of SPIO nanoparticles dispersed in water159. 1 ml of 
500 µg/ml coumarin-6 in ethanol was added to 100 mg magnetite equivalent of SPIO NP 
in 10 ml of water and stirred overnight. The coumarin-6 labeled SPIO nanoparticles were 
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washed thrice in water followed by magnetic separation of nanoparticles. The final 
product was dispersed in 10 ml of water and 5 mg pluronic F127 and observed under a 
fluorescent microscope to confirm the presence of dye-label on particles. 
 
 
 
2.2.2.2. Characterization of SPIO nanoparticles 
The hydrodynamic diameter of SPIO nanoparticles was determined by dynamic 
light scattering. About 1 mg of SPIO nanoparticles was dispersed in 2 ml of deionized 
water by sonication and the dispersion was subjected to particle size analysis using a 
Delsa™ Nano C Particle Analyzer (Beckman, Brea, CA). Measurements were performed 
at 25°C and at a 165° scattering angle. Mean hydrodynamic diameter was calculated 
based on size distribution by weight, assuming a lognormal distribution. For transmission 
electron microscopy (TEM), a drop of an aqueous dispersion of SPIO nanoparticles was 
placed on a Formvar-coated copper grid (150 mesh, Ted Pella Inc. Redding, CA). Excess 
liquid was removed using a filter paper, and the grid was allowed to air-dry. Particles 
were imaged using a JEOL JEM-1210 transmission electron microscope (Peabody, MA). 
The diameters of at least 100 different particles were measured using ImageJ software 
and averaged to determine the mean Feret’s diameter.  
 The form of iron oxide was assessed by Fourier-transformed infrared 
spectroscopy (FT-IR). About 5 mg of SPIO nanoparticles was analyzed using Vertex 70 
FT-IR spectrophotometer (Bruker Optics Inc., Billerica, MA). Scans were performed 
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from 4000 cm-1 to 400 cm-1 and each spectrum was obtained by averaging 16 
interferograms at a resolution of 2 cm−1. The data was collected and analyzed using 
OPUS software (Bruker Optics Inc., Billerica, MA). Magnetic properties were 
determined with an accurately weighed sample of SPIO nanoparticles, which was 
sprinkled on a lightly greased silicon wafer and placed in a vibrating sample 
magnetometer (Micromod Model 3900, Princeton, NJ) operating at room temperature. 
Magnetization curves were recorded in magnetic fields ranging from -1 T to 1 T, at 
increments of 0.002 T. The curve was normalized to the weight of magnetite to obtain the 
saturation magnetization per gram of magnetite. The composition of SPIO nanoparticles 
was estimated using 1,10 phenanthroline-based iron assay160. SPIO nanoparticles were 
dissolved in 12 N hydrochloric acid. The solution was then diluted with distilled water to 
obtain a final acid concentration of 0.2 N. To this acid solution, 10 mg/ml ascorbic acid, 
1.2 mg/ml 1,10 phenanthroline, 22.4 mg/ml potassium hydroxide and 123 mg/ml sodium 
acetate were added in a volume ratio of 1:1:1:1:5. Absorbance of the resultant solution 
was measured at 490 nm using a microplate reader (ELx800 Absorbance Microplate 
Reader, Biotek, Winooski, VT). Commercial iron oxide powder and ferric chloride 
(hexahydrate) solutions in 0.2 N hydrochloric acid were used as standards.  
2.2.2.3. Cell culture studies 
  A549 (human lung adenocarcinoma) and A549-Luc (stable luciferase expressing) 
cells were used in the study. Both cells were propagated using F-12K medium 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic solution and 
maintained at 37 °C and in 5% carbon dioxide.  
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2.2.2.4. Cell death after magnetic hyperthermia 
About 1 million cells were suspended in 500 µl of F-12K (with 10% FBS) and 
mixed with 500 µl SPIO nano or micro aggregates in saline to make a final concentration 
of 1.75 mg/ml magnetite. The suspension was placed in AMF (6 kA/m, 386 kHz) for 5, 
15 or 30 min, maintaining the temperature of the cell suspension between 43 – 46°C. 
Cells not exposed to AMF, with or without SPIO nanoparticles, served as control. 
Additionally, cells were kept in a water bath for 30 min at 46 °C, to serve as conventional 
hyperthermia controls. Magnetic hyperthermia induced using a commercial formulation 
of dextran-coated SPIO (Nanomag®-D-SPIO) was also used for comparison of in vitro 
efficacy. Cells were pelleted 2 hr following treatment, and the amount of LDH released 
by the cells in the supernatant was determined. LDH released by same number of freeze-
thaw lysed cells was used to calculate 100% cell death. In addition, 50,000 treated cells 
were plated per well in a 24-well plate and assayed for cell survival after 24 hours by 
MTS assay. 
2.2.2.5. Instantaneous PI uptake during AMF exposure:  
About 1 million cells were suspended in 500 µl of F-12K (with 10% FBS) and 
incubated with 500 µl nano or micro aggregates or Nanomag® in saline (final 
concentration of 1.75 mg/ml magnetite) at 4°C for 30 minutes. 10 µM PI was added to 
each tube and the treated cells were subjected to 30 minutes of AMF while maintaining 
the cell suspension temperature below 5°C by using an ice bath. Cells not exposed to 
AMF, with or without SPIO nanoparticles, were used as controls. Following AMF 
exposure, cells were immediately washed with buffer, resuspended in medium and kept 
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on ice. PI present in cells was detected in the FL-3 channel of the flow cytometer (BD, 
FACSCalibur™). Data from 10,000 cells in each group were analyzed using Cyflogic 
software. 
2.2.2.6. Reactive oxygen species (ROS) generation  
Immediately prior to the addition of SPIO formulations, 5-(and-6)-chloromethyl-
2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) (7.5 µM) and PI 
were added to the cell suspension. Cells were subjected to flow cytometric analysis after 
2 hours. The deacetylated and oxidized product, 2',7'-dichlorofluorescein, formed due to 
ROS generation in the cells, was detected in the FL-1 channel while PI fluorescence was 
detected in the FL-3 channel.  
2.2.2.7. Western blotting analysis 
Cells were lysed using RIPA buffer containing protease inhibitor cocktail (Sigma) 
on ice. Cell lysates were centrifuged at 13,000 rpm for 10 min to pellet the insoluble 
cellular debris, and the supernatant was analyzed. Protein concentration in the 
supernatant was determined by the bicinchoninic acid assay (Thermo Scientific). Protein 
samples (15 µg) were loaded onto a 4 - 15% Tris-hydrochloride gel (Bio-Rad 
Laboratories) and, after electrophoresis for 40 min at 100 V, transferred onto a 
nitrocellulose membrane (Whatman) using a Criterion blotter (Bio-Rad Laboratories). 
The membrane was blocked with 5% non-fat dry milk in tris-buffered saline containing 
Tween 20 (TBST) for 1 hr. The membrane was then incubated overnight at 4° C with 
primary antibodies against PARP1, cleaved PARP1, HSP70, LC3B, GAPDH-HRP or β-
actin-HRP, diluted in either 5% non-fat dry milk in TBST or 5% BSA in TBST. After 
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three 8-min washes with TBST, the membrane was incubated with horseradish 
peroxidase-conjugated anti-rabbit (for PARP1, cleaved PARP1 and LC3B) or anti-mouse 
(for HSP70) IgG in 5% non-fat dry milk in TBST for 1 hr and then washed three times 
with TBST. Protein bands were then visualized using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). For densitometric quantification, 
immunoblots were digitized on a flatbed scanner and the signal intensities of the 
visualized bands were quantified using ImageJ (NIH) and OriginPro 8 software 
(OriginLab Corporation, Northampton, MA). 
2.2.2.8. Confocal microscopy 
Following incubation with coumarin-6 labeled SPIO nanoparticles and AMF 
exposure, cells were stained with LysoTracker ® red DND-99 (Invitrogen) for 30 
minutes at 37°C or Texas red® -X conjugated wheat germ agglutinin (Invitrogen) for 10 
minutes at 37°C and washed with phosphate buffered saline. Ten µl of the cell suspension 
was added to a glass slide, mounted by a cover glass and sealed with clear nail polish. 
The slides were imaged using a 40X/1.30 numerical aperture oil-immersion objective in 
an Olympus FluoView FV1000 BX2 upright confocal microscope (Olympus 
Corporation). The images were analyzed using FV1000 Viewer software (Olympus 
Corporation) and ImageJ (NIH). 
2.2.2.9. Synthesis of iron oxide microparticles 
Uniform spherical magnetite particles were prepared from ferrous hydroxide gels 
following the procedure of Sugimoto and Matijevic 161. Ferrous hydroxide was first 
precipitated as an aqueous gel, which was then aged at 90°C in the presence of nitrate 
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ion. The final particle size distribution was controlled by the ratio of KOH to Fe(OH)2 
ratio. About 201 mg of KNO3 (Mallinkrodt) was combined with 250 mg of FeSO4.7H2O 
(Sigma-Aldrich) in 10 ml of degassed de-ionized water that was purged with N2. The 
reaction mixture was bubbled with nitrogen until the components were dissolved, and 
then 0.4 ml of 1.25 M KOH (Sigma-Aldrich) was added to produce a green gel. The gel 
was sonicated in a bath sonicator for 5 s, and the sealed vial was then placed in a glycerin 
bath maintained at 90°C (±2°C). After 2 hrs, 38 mg of myristic acid (Aldrich) was added 
to the reaction mixture followed by sonication. The vial was placed in a glycerin bath 
equilibrated at 80°C for 20 min. The mixture was vortexed and sonicated after every 10 
min to redisperse the fatty acid among the particles. After cooling, the coated particles 
were separated from the reaction mixture by rinsing with acetone to remove unreacted 
fatty acid and with deionized water to remove the salt. To the particle dispersion, 40 mg 
of pluronic F127 was added and then sonicated in a bath sonicator for 1 hour to yield the 
final iron oxide microparticles. 
2.2.2.10. PI uptake by cells in rotational magnetic field 
 Rotating magnetic field was generated by mounting a disc neodymium magnet 
diametrically on top of a variable speed magnetic stirrer (set at 500 rpm) 162. About 
10,000 A549 cells were plated in a 24-well plate and after 24 hours, 500 µl of media (F-
12K + 5% FBS) containing 500 µg magnetite equivalent of nano or micro aggregates 
were added to the plated cells. Untreated controls received media without any particles. 
10 µM PI was also added to the wells for detecting cells with compromised membranes. 
Some of the nano and micro aggregate groups were placed on the rotating magnetic field 
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(100 mT, adjusted by changing the distance from the magnet) for 4 minutes. After 
exposure, 0.1 µM calcein AM (to label viable cells) was added to the wells, which were 
then observed under a fluorescent microscope. 
2.2.2.11. In vivo tumor growth studies 
 The study was carried out in compliance with protocol approved by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Female 
BALB/c-nude mice (C.Cg/AnNTac-Foxn1nu NE9; Taconic Farms), four to six weeks of 
age, were used for the studies. 1 million A549-Luc cells were injected subcutaneously in 
the abdominal region of the mice and the tumor dimensions were measured every 
alternate day using digital calipers. The tumor volume (V) was calculated using the 
formula V = 0.5(L × W2), where L and W are the longest and shortest diameters, 
respectively. When the tumor volume reached 150 mm3, 40 µl of saline or 225 µg 
magnetite equivalent of nano or micro aggregate suspension was injected intratumorally 
and allowed to distribute inside the tumor for 24 hours 163. After 24 hours, animals in the 
MH groups were anesthetized and their abdominal region (tumor region) was exposed to 
AMF (6 kA/m, 386 kHz) for 30 minutes. The tumor temperature was measured using an 
infrared camera (Infrared solutions) where snapshots of the AMF exposed tumor region 
of the mice were acquired every 2 minutes. The temperature elevation in the tumor 
during MH was added to the normal body temperature (assumed to be 37°C) to obtain the 
calculated tumor temperatures. Tumor volumes were measured every alternate day after 
treatment by calipers and bioluminescence imaging (IVIS Spectrum, PerkinElmer) of the 
tumors was performed every week. Development of 1000 mm3 tumors or 30 days after 
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cell injection (whichever came first) marked the end of the study for each animal. At the 
end of the study, the tumors were excised, formalin fixed, paraffin embedded, sectioned 
and stained with Prussian blue (for iron) or hematoxylin and eosin (for cellular structure). 
In a separate set of animals, the tumors were excised immediately after MH treatment and 
processed for Prussian blue and hemetoxylin-eosin staining. 
 
2.2.2.12. Statistical analysis 
Statistical analyses were performed using one-way ANOVA, followed by 
Bonferroni-Holm testing for comparison between individual groups. A probability level 
of P < 0.05 was considered significant. 
 
2.3. Results and Discussions 
2.3.1. SPIO nanoparticle aggregate size affects the mechanism of cell 
kill by MH 
To study the effect of aggregation on therapeutic performance, we used a 
synthetic technique that facilitated the aggregation of SPIO nanoparticles. The final 
product was fractionated into micro and nano size aggregates. Nano aggregates had an 
average hydrodynamic diameter of 207 ± 3 nm. Micro aggregates had an average size of 
1052 ± 65 nm. The aggregates were composed of 12 ± 3 nm iron oxide cores (Figure 
2.1), which were confirmed to be magnetite (Figure 2.2a). Both nano and micro 
aggregates had high saturation magnetization of 72.9 and 67.7 emu/g of magnetite, 
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respectively, with negligible remanence (1.64 and 1.44 emu/g of magnetite, respectively) 
and coercivity (2.73 and 2.36 Oe), verifying their superparamagnetic nature (Figure 
2.2b). The heating profiles for the two fractions were virtually identical (Figure 2.2c), 
further verifying their similar magnetic properties. 
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Figure 2.1 Size of SPIO aggregates. (a) Representative TEM image of SPIO nano 
aggregate showing a 100-200 nm aggregate composed of 12 ± 3 nm SPIO core 
(average Feret’s diameter of 100 different SPIO cores measured using ImageJ 
software). Scale bar, 50 nm. (b) TEM image of micro aggregates showing a large 
electron dense particle (about 1.5 µm in size). Scale bar, 500 nm. (c) Higher 
magnification image of the boxed area of (B) demonstrating that the micro aggregates 
are also composed of the smaller SPIO cores tightly packed together to form the larger 
structure. Scale bar, 50 nm. (d) TEM image of uranyl acetate counterstained SPIO 
nano aggregates showing that the SPIO cores are enveloped by myristic acid/pluronic 
F127 coating to form stable aggregates. The size of micro aggregates interfered with 
the visualization of coating on them. (e) Average hydrodynamic diameter of nano and 
micro aggregates measured by DLS. Data shown is mean ± SD of five individual size 
measurement runs, with each run recording 150 size events. 
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Figure 2.2 Characterization of SPIO aggregates. (a) FT-IR spectrum of SPIO 
nanoparticles. Presence of characteristic magnetite bands at 570 cm-1 and 400 cm-1 (arrow) 
and absence of maghemite bands at 700 cm-1 and 630-660 cm-1 (box) indicate that the primary 
form of iron oxide is magnetite1. (b) Magnetization curves of nano aggregates (NA) and micro 
aggregates (MA) recorded on a vibrating sample magnetometer. The curve was normalized to 
the weight of magnetite added to obtain saturation magnetization per gram of magnetite. The 
sigmoidal curve is characteristic of superparamagnetic substances. The data shows that the 
saturation magnetization of nano and micro aggregates was similar (~70 emu/g magnetite). 
Additionally, exposure of micro aggregates to AMF did not alter their saturation 
magnetization or superparamagnetic properties. (c) Heating rates of nano and micro 
aggregates dispersed in an alternating magnetic field of 6 kA/m and operating at a frequency 
of 386 kHz. The initial temperature was equilibrated to 37°C, and temperature of the SPIO NP 
dispersion was sampled at 5 second intervals using a fluoroptic probe following the 
application of magnetic field. The magnetic field was stopped when the temperature reached 
about 45.5°C and restarted at 43.5°C. The graph shows the similarity in the heating profiles of 
nano and micro aggregates during the three AMF on/off cycles. 
  42 
Nano aggregate-mediated hyperthermia resulted in a time-dependent decrease in 
cell survival. The lactate dehydrogenase (LDH) release was not significantly increased at 
two hours following MH treatment (Figure 2.3a); however, less than 10% of the treated 
cells survived at 24 hours (Figure 2.3b). Similar inefficient early LDH release and higher 
cell death at 24 hours was also observed in cells subjected to conventional hyperthermia 
or MH using a commercial well-dispersed 100-nm SPIO nanoparticle formulation 
(Nanomag®). This was not surprising, given that hyperthermia has been shown to induce 
apoptotic cell death, a slow process that takes several hours 164-166. Both Nanomag®-
mediated MH and conventional hyperthermia resulted in PARP1 cleavage (Figure 2.4), 
confirming the induction of apoptosis with these treatments. However, nano aggregate 
induced MH resulted in a decrease in the levels of intact 116 kDa PARP1 protein (Figure 
2.4, Figure 2.5a), without a concomitant increase in levels of the cleaved PARP1 
fragment (89 kDa) (Figure 2.4, Figure 2.5b), a marker for caspase-dependent apoptosis 
167,168
. The lysosomal enzyme cathepsin, which is released after lysosomal rupture such as 
during autophagy 169, can cleave PARP1 into fragments of different sizes (44, 55, 62 and 
74 kDa) 170, and thereby decrease PARP1 levels without a detectable increase in the 89 
kDa fragment. Expression of LC3B-II (Figure 2.4), an autophagy marker 171, further 
points to autophagy as the primary cell kill mechanism with nano aggregate-mediated 
MH. 
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Figure 2.3 Effect of SPIO nanoparticle aggregate size on the mechanism of cell kill by 
MH. Effect of nano aggregate (NA), micro aggregate (MA) and commercial 
nanoparticle (Nanomag®; NM)-mediated MH and conventional hyperthermia (WBH) 
on (a) cell death quantified by LDH release from the cells 2 hours after treatment and 
(b) cell survival 24 hours after treatment measured by MTS assay. A549 cell 
suspension containing different SPIO formulations were subjected to 5 min, 15 min or 
30 min of AMF after the suspension temperature reached 43°C. Untreated cells or 
cells incubated with SPIO formulations without AMF exposure (-MH) were used as 
controls. Conventional hyperthermia involved maintaining cells at 46°C for 30 min on 
a water bath. Data shown is mean ± S.D., n = 3. * P < 0.00001 vs. cells exposed to 30 
min heating with different treatment; # P < 0.001 vs. corresponding unheated control.  
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Figure 2.4 Western blotting. Western blotting analysis of expression of PARP1 (116 kDa), 
cleaved PARP1 (89 kDa), LC3B-I (16 kDa), LC3B-II (14 kDa), GAPDH (37 kDa) and beta 
actin (44 kDa) 24 hours after MH treatment as in Figure 2.3a and 2.3b.  
Figure 2.5 Quantitation of the western blot (Figure 2.4). Band intensity of (a) PARP1, 
(b) cleaved PARP1 and (c) GAPDH after different treatments. The band intensity was 
normalized to the levels of beta actin in the cell lysate. NA = nano aggregates, MA = micro 
aggregates, NM = Nanomag® and WBH = conventional hyperthermia.  
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Autophagy is a form of programmed cell death mediated by the lysosomal 
machinery and intracellular membrane rearrangement, leading to massive degradation of 
cellular components 172. Autophagy involves sequesteration of cytoplasmic components 
in a membrane vesicle called autophagosome, which then fuses with the lysosome to 
form an autolysosome. Proteases within the autolysosome degrade the sequestered 
cytoplasmic components. Oxidative stress has been shown to play an important role in 
inducing autophagy 173-175. We determined the level of reactive oxygen species (ROS) 
produced by cells subjected to different treatments. The ROS levels remained unchanged 
after conventional hyperthermia and Nanomag®-induced MH. However, nano aggregates 
resulted in elevated cellular ROS levels (Figure 2.6). One of the effectors of oxidative 
stress is GAPDH 176, which causes an elevation of cellular glycolysis and drives 
autophagy 177. MH using SPIO nanoparticle formulations resulted in elevated GAPDH 
protein levels, and this increase was greatest in cells subjected to nano aggregate-
mediated MH (Figure 2.4, Figure 2.5c).   
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With micro aggregates, we observed significant LDH release from treated cells at 
2 hours following MH treatment (~90% cell kill with 30 min of MH, Fig. 1a). Acute 
LDH release with micro aggregates indicated that the cell membrane was compromised 
rather quickly, pointing to a necrotic cell death mechanism 178. We hypothesized that 
rotational/oscillatory movement of micro aggregates in alternating magnetic field (AMF) 
Figure 2.6 ROS generation after different treatments. CM-H2DCFDA was added to 
A549 cells immediately before exposure to alternating magnetic field and after 2 
hours, the cells were analyzed by flow cytometry to determine ROS levels. The graph 
shows a representative ROS profile of cells after treatment. Neither conventional 
hyperthermia nor Nanomag® mediated MH resulted in the elevation of ROS 
production relative to that in untreated cells. However, both nano and micro aggregate 
mediated MH led to an elevation of ROS levels in the cells. 
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caused acute mechanical cell damage and LDH release. Such a mechanism would be 
temperature-independent, since the particle movement is dependent only on the strength 
of the magnetic field. To probe for this possibility, cells incubated with SPIO aggregates 
were subjected to AMF at a low temperature (<5°C). Acute membrane damage induced 
by this treatment was determined by monitoring the ‘instantaneous’ propidium iodide 
(PI) uptake by treated cells 162. Only the cells treated with micro aggregates demonstrated 
instantaneous PI uptake in the absence of temperature elevation (Figure 2.7a). Neither 
nano aggregates (Figure 2.7b) nor Nanomag® (Figure 2.8) was effective in inducing 
instantaneous PI uptake.  
 
 
 
Figure 2.7 Instantaneous PI uptake. Flow cytometric analysis of instantaneous PI 
uptake by cells incubated with (a) micro aggregates and (b) nano aggregates and 
subjected to AMF under low temperature (<5°C). PI was added to the cell suspension 
immediately prior to AMF exposure (30 min), washed after treatment to eliminate the 
excess PI and analyzed by flow cytometry. Data shown is representative PI profile of 
the different treatments (n = 3). Micro aggregates showed an increase in PI positive 
population after AMF exposure. 
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Additionally, while conventional hyperthermia and Nanomag® or nano aggregate- 
induced MH caused an elevation of heat shock protein 70 (Hsp70), micro aggregate-
mediated MH showed no such increase (Figure 2.9a and 2.9b). This further verified the 
role of temperature elevation as the primary mechanism of cell death with sub-micron 
aggregates and a temperature-independent cell death mechanism with micro aggregates. 
Induction of Hsp70 expression also suggests the possibility of triggering Hsp70-mediated 
resistance to thermotherapy 179,180. 
Figure 2.8 Instantaneous PI uptake. Flow cytometric analysis of instantaneous PI 
uptake by cells incubated with Nanomag® and subjected to AMF under low 
temperature (<5°C). PI was added to the cell suspension immediately prior to AMF 
exposure (30 min), washed after treatment to eliminate the excess PI and analyzed by 
flow cytometry. Data shown is representative PI profile of the different treatments (n 
= 3). No detectable difference in the PI profile was observed between the different 
treatments. 
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2.3.2. Micro aggregates cause membrane damage through direct 
membrane contact 
To further study the mechanism of membrane damage induced by micro 
aggregates, we determined the cellular distribution of the aggregates. Coumarin-6 (a 
Figure 2.9 Western blotting of HSP70 and beta actin. (a) Western blotting analysis of 
expression of HSP70 (70 kDa) and beta actin (44 kDa), 24 hours after MH treatment 
(as in Figure 2.3a and 2.3b). (b) Quantitation of HSP70 levels from (A) normalized to 
beta actin. While conventional hyperthermia and nano aggregate or nanomag® 
mediated MH led to an increase in HSP70 expression in the cells, micro aggregate 
mediated MH did not elevate the protein level relative to that in untreated cells. 
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lipophilic green fluorescent dye) was incorporated in SPIO nanoparticles to aid in 
visualization of particles 181. Confocal microscopic images showed the presence of 
aggregates on cell surfaces and in the lysosomes (Figure 2.10a). In the absence of AMF, 
incubation with micro aggregates did not affect the cell membrane integrity (Figure 2.8b). 
Exposure to AMF caused blebbing of the membrane at points where the aggregates 
contacted the cell membrane (Figure 2.10b). The membrane blebs were large and 
characteristic of necrotic blebs 182. Additionally, the blebbed cells also stained positive 
for PI, indicating the loss of membrane integrity in these cells (Figure 2.11). 
We postulated that micro aggregates caused cell membrane damage through 
physical motion of the aggregates that are bound to cell membrane. Alternatively, cell 
membrane damage could also be the result of intense local heat generation by the 
aggregates 183,184. To test these possibilities, solid iron oxide particles (iron oxide 
microparticles) were synthesized with similar dimensions as micro aggregates (Figure 
2.12). These particles had ferromagnetic properties, characterized by a hysteresis loop in 
the induced field as a function of applied field and by a larger remanence than SPIO 
nanoparticles (Figure 2.13). Concentration of iron oxide microparticles used in cell 
culture experiments was adjusted to achieve an in vitro heating profile similar to that with 
micro aggregates. Despite similar temperature elevation as micro aggregates, iron oxide 
microparticles were ineffective in inducing tumor cell kill (7% vs 90% for micro 
aggregates) (Figure 2.14a). 
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Figure 2.10 Micro aggregate mediated membrane damage through direct contact. 
(a) Confocal microscopic images of cells incubated with coumarin-6 labeled SPIO micro 
aggregates (green). Lysosomes were stained with Lysotracker red®. Representative images 
showing the location of lysosomes (left), micro aggregates (center) and their colocalization 
(right) are shown. The merged image shows aggregates on the surface of cells (white arrows) 
and in lysosomes (yellow arrows). Scale bar, 5µm. (b) Confocal microscopy of cells incubated 
with coumarin-6 labeled SPIO micro aggregates before (top) and after (bottom) AMF 
exposure at low temperature (<5°C). The cell membrane was labeled with Texas red® labeled 
wheat germ agglutinin (left). The coumarin-6 labeled SPIO micro aggregates (center) were 
present both on the cell membrane and inside the cells. The cell membrane was intact in cells 
incubated with particles in the absence of AMF (top right), indicated by the smooth cell 
membrane staining. Exposure to AMF resulted in cell membrane blebbing (bottom right, 
yellow arrows) at the sites where the aggregates contacted the cell membrane (white arrows). 
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Figure 2.11 Micro aggregate mediated membrane damage through direct contact 
(PI uptake). Phase contrast (left) and fluorescence microscopic image (middle) of 
cells incubated with SPIO micro aggregates and PI and exposed to low temperature 
AMF. The merged image (right) shows PI positive, extensively blebbed cells (black 
arrows) and the healthy cells devoid of blebbing or PI staining. 
Figure 2.12 Characterization and in vitro effects of SPIO microparticles (TEM 
image). (a) Representative TEM image of iron oxide microparticles. The 
microparticles were spherical and about 1 µm in size. Scale bar, 200 nm. (b) The 
boxed area of (A) is magnified to show that unlike the micro aggregates (Figure 2.1), 
the microparticles were solid and not composed of smaller iron oxide cores. Scale bar, 
100 nm. 
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Figure 2.13 Characterization and in vitro effects of SPIO microparticles 
(Magnetization curve). Magnetization curve of iron oxide normalized to the weight of 
magnetite added to obtain saturation magnetization per gram of magnetite. The open 
hysteresis loop with higher remanence (6.08 emu/g magnetite) than the nano and 
micro aggregates (1.64 and 1.44 emu/g of magnetite, respectively) verified that the 
iron oxide microparticles were not superparamagnetic in nature and generated heat 
predominantly by hysteresis heating rather than by relaxation phenomena when placed 
in an AMF. 
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Due to their ferromagnetic nature, iron oxide microparticles do not rotate in AMF 
but instead undergo hysteresis heating 67. Because their heating rates and sizes were 
similar to that of micro aggregates, the intensity of local heat produced is also expected to 
be similar. However, the ineffectiveness of these particles in killing cells despite their 
association with the cells (Figure 2.14b), suggests that intense local heating is not the 
likely mechanism of cell membrane damage with micro aggregates. Also, as noted above, 
micro aggregates induced cell membrane damage even when the cell suspension was 
maintained below 5°C; the cold medium should act as an effective heat sink, thereby 
Figure 2.14 Characterization and in vitro effects of SPIO microparticles (Cell death). 
(a) Effect of iron oxide microparticle mediated MH on cell death quantified by LDH 
release from the cells 2 hours after treatment. A549 cell suspension containing iron 
oxide microparticles was subjected to 30 min of MH. Untreated cells or cells 
incubated with microparticles without AMF exposure were used as controls. Though 
MH using iron oxide microparticles resulted in higher cell death than control, the 
increase was almost negligible compared to SPIO micro aggregate mediated MH (7% 
vs 90% respectively). (b) Microscopic image of iron oxide microparticles (black dots) 
associated with A549 cells. 400X magnification. 
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minimizing any local temperature elevation. Our results thus suggest that micro 
aggregates induce acute cell kill through mechanical disruption of cell membrane. 
Theoretical estimations show that while the energy requirements for creating a membrane 
pore are not easily overcome by 100 nm magnetic particles, the energetic restriction 
becomes less stringent with increasing particle size 185. Thus, it is much more favorable 
for a rotating or oscillating micro aggregate to disrupt the cell membrane integrity than a 
nano aggregate. Quite recently, a similar membrane damaging effect (termed 
‘magnetoporation’ and ‘magnetolysis’) was described for polymer-coated carbon 
nanotubes that were subjected to a rotating magnetic field 162. Interestingly, the polymer 
coated multi-walled carbon nanotubes formed aggregates (or ‘bundles’) that were in the 
same size range as micro aggregates used here. 
To further determine the possibility of cell membrane damage induced by the 
motion of micro aggregates, we used the procedure described by Liu et al. 162, where cells 
incubated with nano or micro aggregates and PI were subjected to a rotating magnetic 
field. Only 3 min of rotating magnetic field exposure with micro aggregates resulted in a 
dramatic increase in the proportion of PI positive cells (Figure 2.15). This further 
substantiates the possibility that micro aggregates in motion can alter cell membrane 
integrity. 
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2.3.3. Micro aggregate induced magnetic hyperthermia inhibits tumor 
growth in vivo 
To determine whether differences in aggregate size affects in vivo therapeutic 
efficacy as well, we evaluated the anticancer efficacy of micro and nano aggregates in 
mice bearing subcutaneous A549 tumor xenografts. Animals receiving the aggregates 
without exposure to AMF served as control groups. Tumor temperatures were monitored 
using infrared thermometry and the magnetic field conditions were optimized to ensure 
that the tumor temperature did not increase beyond 46°C. The average tumor temperature 
was 43.5°C in both the micro and nano aggregate groups, with the highest temperature 
reached being 45.5°C and 45.7°C, respectively (Figure 2.16). Nano aggregate-mediated 
MH resulted in a moderate decrease in tumor growth rate (p = 0.085) relative to that in 
animals that received nano aggregates but were not exposed to AMF. Micro aggregate-
mediated MH showed significant effectiveness (p < 0.001), with near complete inhibition 
Figure 2.15 Effect of rotating magnetic field (RMF) on instantaneous cell membrane 
damage and PI uptake. A549 cells were incubated with PI and (a) phosphate buffered 
saline, (b) nano aggregates without RMF, (c) nano aggregates subjected to 3 min of 
RMF, (d) micro aggregates without RMF exposure and (e) micro aggregates exposed 
to RMF for 3 minutes. Immediately after RMF exposure, the cells were washed with 
phosphate buffered saline, 0.1 µM calcein AM added to the cell media and imaged 
under fluorescent microscope. Calcein AM labels the live cells green (left) and PI 
labels the nucleus of the dead cells red (center). The merged image (right) shows that 
unlike the other treatments, micro aggregates subjected to a RMF was successful in 
disrupting the cell membrane integrity in a large number of cells. 
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of tumor growth (Figure 2.17). The results from the bioluminescence imaging reinforced 
this finding, with micro aggregate-mediated MH being highly effective in decreasing the 
tumor-associated luminescence (Figure 2.18). Histological analysis of the tumor sections 
revealed that micro aggregate-mediated MH resulted in the formation of “hollow” 
tumors, with a large central acellular core and a small outer rim of cells (Figure 2.19, 
Figure 2.20). Immediately after exposure to AMF, cells surrounding the SPIO aggregates 
(confirmed by Prussian blue staining) were characterized by altered morphology, 
decreased cell volume, and increased nuclear density (Figure 2.21b,d). Tumor tissue 
sections from the control group (injected with micro aggregates but not exposed to AMF) 
showed no such changes in the cellular morphology around the SPIO aggregates (Figure 
2.21a,c). Because all the experimental parameters (dose of SPIO, duration of AMF 
exposure and the temperature elevation) were similar for both nano and micro aggregates, 
the enhanced effectiveness of micro aggregates is likely due to temperature-independent 
membrane damage.  
These in vivo results thus confirm that larger aggregates are more effective in 
killing tumor cells than smaller sub-micron size aggregates. Intravenous delivery of 
micro aggregates is likely not practical due to concerns of embolism 110,186 and because 
the particle size is too large to take advantage of the enhanced permeation and retention 
effect 146. However, the particle size range of micro aggregates is particularly suitable for 
inhalation delivery 109 to treat lung tumors 187,188. Alternately, an in situ aggregation 
approach can also be envisioned, where sub-micron size particles injected intravenously 
aggregate into micron size aggregates in the tumor microenvironment. 
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Figure 2.16 Tumor temperature monitoring using infrared camera. Representative 
photograph of a mouse placed in the radiofrequency coil (left) during nano aggregate 
(NA) (top) or micro aggregate (MA) (bottom) mediated MH. The black arrow 
indicates the location of the subcutaneous tumor xenograft. The temperature elevation 
during MH was measured using infrared thermometry. Infrared thermometric images 
of the temperature difference before and at the end of MH treatment is shown (right). 
The tumor temperature (black oval) was calculated for both nano and micro aggregate 
mediated MH (table). Note that the elevated temperature at the edges of the coil is due 
to the heating of the coil during AMF exposure. 
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Figure 2.17 Effect of SPIO aggregate mediated MH on in vivo tumor growth. The 
tumor growth was monitored every alternate day after MH treatment. The graph 
shows the tumor growth with different treatments as a function of time after treatment. 
Data shown is mean ± S.D., n = 6. * P < 0.001 and # P < 0.1 vs. control. 
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Figure 2.18 Bioluminescence imaging of mice. Mice were injected with (a) saline, (b, c) 
SPIO nano aggregates and (d, e) SPIO micro aggregates intratumorally when the tumor 
volumes reached 150 mm3. After 24 hours, the (c) nano aggregate and (e) micro aggregate 
treated animals were subjected to magnetic hyperthermia for 30 minutes. Tumor 
bioluminescence was measured before MH treatment (Day 0) and on days 2, 7, 14, 21 and 28. 
The images are from an animal in each group monitored over 4 weeks after treatment. The 
bioluminescence intensity of all images are scaled as shown in the right. 
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Figure 2.19 Histology of tumors exposed to MH treatment (micro aggregate). 
Hematoxylin and eosin (H&E) staining (left) of a tumor after 30 days of micro 
aggregate mediated MH. The tumor is partially acellular due to the MH treatment. 
Prussian blue staining (right) performed on the subsequent section (5µm apart) shows 
the presence of SPIO particles at the necrotic margins of the tumor. 
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Figure 2.20 Histology of tumors exposed to MH treatment (controls). Hematoxylin 
and eosin staining (left) and prussian blue staining (right) performed on the 
subsequent section (5µm apart) of tumors collected at the end of the in vivo study. (a) 
nano aggregates without MH, (b) nano aggregates with MH and (c) micro aggregates 
without magnetic hyperthermia. All the tumors are highly cellular unlike the micro 
aggregate mediated MH treated tumors (Figure 2.16). 
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Figure 2.21 Histology of tumors exposed to MH treatment (cell damage). (a) H&E 
staining of a tumor section (400X magnification) from animals receiving no treatment. 
The tumor cells have a ‘swollen’ appearance with large lightly stained nucleus. (b) 
H&E staining (400X magnification) of a micro aggregate injected tumor that was not 
exposed to an AMF. The micro aggregates can be identified by their brown color. 
Cells adjacent to the particles have similar morphology as the untreated tumor (a). (c) 
H&E staining (400X magnification) of a tumor collected immediately after micro 
aggregate mediated MH. Cells around the particles have altered morphology 
characterized by cell shrinkage and denser nuclear stain. (d) Lower magnification 
(100X) of (c) showing a distinct region around the micro aggregates (black bordered 
area) where the cells have a different morphology compared to the rest of the tumor. 
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2.4. Conclusions 
Inorganic nanoparticles have the propensity to aggregate when introduced into a 
biological milieu. Our studies showed that the particle size of aggregates affects the 
therapeutic performance of SPIO nanoparticles. Well-dispersed SPIO nanoparticles 
induce apoptosis, similar to that observed with conventional hyperthermia. Nanometer 
size aggregates, on the other hand, induce temperature-dependent autophagy through 
generation of ROS. Micron size aggregates caused rapid membrane damage and acute 
cell kill, likely due to physical motion of the aggregates in AMF. This novel mechanism 
of cell kill induced by micro aggregates translated into effective in vivo tumor growth 
inhibition. Overall this work highlights the potential for developing highly effective 
anticancer therapeutics through simple yet often overlooked modifications of delivery 
systems such as their state of aggregation. 
 
   
  66 
Chapter 3 
EFFECTIVE ELIMINATION OF CANCER STEM CELLS BY MAGNETIC 
HYPERTHERMIA 
Tanmoy Sadhukha a, Lin Niu a, Timothy Scott Wiedmann a and Jayanth Panyam a,b 
a Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455  
b Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455  
 
 
 
Running Title: Magnetic Hyperthermia Effectively Eliminates Cancer Stem Cells 
 
 
Keywords: Superparamagnetic iron oxide, Magnetic Hyperthermia, Cancer Stem Cells, 
Necrosis, Reactive Oxygen Species, Mammosphere, Clonogenicity, Tumorigenicity, 
Aldehyde Dehydrogenase 
 
 
  
  
  67 
3.1. Introduction 
A number of recent studies suggest that tumors consist of a minor population of 
stem-like cells (cancer stem cells; CSCs) that are capable of generating and maintaining a 
tumor in its entirety 189. These cells have the capacity for asymmetric cell division, 
generating one identical daughter cell and another that is committed to a distinct 
differentiation pattern. The latter undergoes a series of divisions and differentiation steps 
that result in the generation of terminally differentiated cell populations. Cells in the 
intermediate states are referred to as progenitors, transit cells or transit amplifying cells 
190
. All of these phenotypes, collectively termed tumor-initiating cells, have the potential 
to give rise to a complete tumor. CSCs are resistant to conventional chemotherapy and 
can initiate tumor recurrence following treatment 191. CSCs possess several defense 
mechanisms including overexpression of efflux pumps that can eliminate cytotoxic drugs 
192
, increased expression of DNA-repair proteins that can counteract DNA damage 193, 
elevated anti-oxidant concentrations to defend against reactive oxygen species (ROS) 194, 
and low rate of cell division 195. Tumors can become enriched in CSCs after conventional 
treatments 193,196, which could account for frequent tumor relapse observed in many 
cancers.  
Hyperthermia, which utilizes elevated temperatures in the range of 41 – 46° C to 
kill tumor cells 36, has been shown to improve treatment response and survival when used 
in combination with radiotherapy, surgery and/or chemotherapy 46,197. In mouse tumor 
models, addition of local hyperthermia significantly increased the sensitivity of CSCs to 
radiotherapy 198. Magnetic hyperthermia is a related approach that utilizes 
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superparamagnetic iron oxide nanoparticles (SPIO NPs) placed in an alternating magnetic 
field to generate heat for a highly localized tumor cell kill 58. Magnetic hyperthermia is 
currently in clinical trials in Europe for glioblastoma as well as prostate and pancreatic 
cancers 199. While a number of previous studies have demonstrated the anticancer 
efficacy of magnetic hyperthermia 200-203, the effect of magnetic hyperthermia on CSCs 
has not been reported to date. Using various in vitro and in vivo assays, we evaluated the 
ability of SPIO NP-mediated magnetic hyperthermia to effectively eliminate CSCs.  
3.2. Experimental Section 
3.2.1. Materials 
Ferrous chloride tetrahydrate, ferric chloride hexahydrate, myristic acid, Pluronic 
F127, ascorbic acid, potassium hydroxide, 1,10 phenanthroline and sodium acetate were 
purchased from Sigma (St. Louis, MO). Penicillin/streptomycin, fetal bovine serum, 
RPMI 1640, Dulbecco’s phosphate buffered saline (DPBS), F-12K (Kaighn’s 
modification), MEM, non-essential amino acids, sodium pyruvate and trypsin-EDTA 
solution were obtained from Invitrogen Corporation (Carlsbad, CA). Cytotox 96® non-
radioactive cytotoxicity assay kit was purchased from Promega (Madison, WI).  
3.2.2. Methods  
3.2.2.1. Synthesis of water-dispersible SPIO NPs  
A stable aqueous dispersion of SPIO NPs was prepared from iron chlorides as 
previously described 204. In brief, 0.82 g of ferric chloride hexahydrate and 0.33 g of 
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ferrous chloride tetrahydrate were dissolved in 30 ml of degassed and nitrogen-purged 
water, and 3 ml of 5 M ammonium hydroxide was added drop-wise to this solution and 
stirred for 30 minutes. Iron oxide nanoparticles formed were washed three times with 
nitrogen-purged water (each wash followed by magnetic separation of nanoparticles), 
sonicated in a water bath sonicator for 2 min, and heated to 80°C. About 100 mg of 
myristic acid was added to the heated mixture and stirred for another 30 min. Particles 
were washed twice with acetone to remove excess myristic acid, followed by two 
additional washes with water to remove excess acetone. Myristic acid-coated particles 
were then suspended in 30 ml water, and 100 mg of pluronic F127 was added and the 
mixture was stirred overnight. The final dispersion was lyophilized (Labconco, FreeZone 
4.5, Kansas City, MO) to obtain SPIO NPs. Every step of the synthesis was carefully 
conducted to minimize exposure to atmospheric oxygen. 
3.2.2.2. Characterization of SPIO NPs 
Dynamic light scattering was used to determine the hydrodynamic diameter of 
SPIO NPs. About 0.5 mg/ml of SPIO NPs dispersed deionized water was subjected to 
particle size analysis using a Delsa™ Nano C Particle Analyzer (Beckman, Brea, CA). 
Transmission electron microscopy (TEM) of SPIO NPs was performed using a JEOL 
JEM-1210 transmission electron microscope (Peabody, MA). A drop of an aqueous 
dispersion of SPIO NPs was placed on a Lacey carbon-coated copper grid (300 mesh, 
Ted Pella Inc. Redding, CA) and allowed to air-dry before imaging. Diameters of 100 
different particles were measured from different TEM images using ImageJ software. The 
average diameter along the horizontal axis was determined as the mean Feret’s diameter. 
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The mean crystallite size of SPIO NPs was calculated from their X-ray diffraction 
pattern. SPIO NPs were subjected to a Cu-Kα radiation (45 kV, 40 mA) in a wide-angle 
powder x-ray diffractometer (D5005, Siemens, Madison, WI). The instrument was 
operated in the step-scan mode in increments of 0.05° 2θ over an angular range of 10 to 
100° 2θ with a dwell time of 1 second for each scan step. Data analysis was performed 
using OriginPro 8 software (OriginLab Corporation, Northampton, MA). Five highest 
peaks (at 30.1°, 35.5°, 43.1°, 57.1° and 62.7° 2θ) were fit using the pseudo-Voigt profile 
function, which is a linear combination of the Gaussian and Lorentzian components of 
the diffraction peaks. The Scherrer equation was utilized to determine the mean particle 
size of SPIO NPs 205.  
 Fourier-transformed infrared spectroscopy (FT-IR) of SPIO NPs was performed 
using Vertex 70 FT-IR spectrophotometer (Bruker Optics Inc., Billerica, MA). About 5 
mg of SPIO NPs were added to the FT-IR stage and scanned from 4000 cm-1 to 400 cm-1. 
Each spectrum was obtained as an average of 16 interferograms at a resolution of 2 cm−1 
and analyzed using OPUS software (Bruker Optics Inc., Billerica, MA). Magnetic 
properties were determined using a vibrating sample magnetometer (Micromod Model 
3900, Princeton, NJ) operating at room temperature. Accurately weighed samples of 
SPIO NPs was sprinkled on a lightly greased silicon wafer and their magnetization curves 
were recorded in magnetic fields ranging from -1 T to 1 T, at increments of 0.002 T. 
Saturation magnetization per gram of magnetite was calculated from the magnetization 
curves normalized to the weight of magnetite added. The composition of SPIO NPs was 
estimated using 1,10 phenanthroline-based iron assay 160. About 5 mg of SPIO NPs were 
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dissolved in 12 N hydrochloric acid and then diluted with distilled water to obtain a final 
acid concentration of 0.2 N. 10 mg/ml ascorbic acid, 22.4 mg/ml potassium hydroxide, 
123 mg/ml sodium acetate and 1.2 mg/ml 1,10 phenanthroline were added to the SPIO 
NP solution in a volume ratio of 1:1:5:1:1. Absorbance at 490 nm was recorded using a 
microplate reader (ELx800 Absorbance Microplate Reader, Biotek, Winooski, VT) and 
the iron content was analyzed using ferric chloride (hexahydrate) solutions in 0.2 N 
hydrochloric acid as standards.  
3.2.2.3. Magnetic heating rate 
SPIO NPs were dispersed in 1 ml of Hank’s F-12K medium or in 1 ml of molten 
3% agarose, which was then allowed to form a gel in 10 mm X 75 mm disposable 
borosilicate glass cell culture tubes. Magnetic heating was performed using an induction 
heating system (1 kW Hotshot, Ameritherm Inc., Scottsville, NY) by placing the 
suspension at the center of a multiturn copper coil that generated the alternating magnetic 
field (nominal magnetic field strength of 6 kA/m and frequency of 386 kHz). The 
temperature change was measured using a fluoroptic® probe (Lumasense Technologies, 
Santa Clara, CA). Samples were thermally equilibrated to 37°C before exposure to the 
field.  
3.2.2.4. Cell culture studies 
 A549 (human lung adenocarcinoma) and MDA-MB-231 (human mammary 
adenocarcinoma) cells were used in the study. A549 cells were propagated using F-12K 
medium supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic solution. 
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MDA-MB-231 cells were grown in MEM supplemented with 10% FBS, 1% non-
essential amino acids, 1% sodium pyruvate and 1% antibiotic solution. Both cell lines 
were maintained at 37°C and in 5% carbon dioxide.  
3.2.2.5. Effect of magnetic hyperthermia on CSCs  
3.2.2.5.1. Side population determination 
Following magnetic hyperthermia, A549 cells were centrifuged and resuspended 
in prewarmed 1 ml DMEM with 2% FBS and 10 mM HEPES. Hoechst 33342 dye was 
added at a concentration of 5 µg/ml. In each treatment group, one sample was pretreated 
with 2 µM tariquidar, an inhibitor of Hoechst efflux. Cells were then incubated at 37°C 
for 90 min with occasional shaking. Cells were then washed with chilled HBSS with 2% 
FBS and 10 mM HEPES buffer and resuspended in chilled buffer. 7AAD was added to 
the sample tubes before flow cytometric analysis to gate for live cells. Flow analysis was 
carried out on a FACSDiva (BD Biosciences); Hoechst 33342 dye was excited at 357 nm 
and the fluorescence was measured at 402-446 nm (blue) and 650-670 nm (red) 
wavelengths 206.  
3.2.2.5.2. Mammosphere assay 
Following magnetic hyperthermia, MDA-MB-231 cells were washed and 
resuspended in cell culture medium. About 3000 live cells (counted by trypan blue 
exclusion) were plated in ultra-low adhesion 6-well plates with 2 ml mammosphere 
formulation (Dulbecco's modified Eagle's medium/F-12 medium supplemented with 10 
ng/ml human-fibroblast growth factor, 20 ng/ml recombinant human epidermal growth 
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factor, 0.4% bovine serum albumin, 5 µg/ml insulin and 1% antibiotics). The number of 
mammospheres formed was counted under a light microscope 5 days after treatment 207.  
3.2.2.5.3. Aldehyde dehydrogenase assay  
Thirty million MDA-MB-231 cells were sorted based on their levels of aldehyde 
dehydrogenase (ALDH) enzyme using the ALDEFLUOR® kit (STEMCELL 
Technologies Inc., Vancouver, Canada) 208. Prior to sorting, 5 µl of the activated reagent 
was added to each milliliter of the cell suspension (1 million cells/ml), mixed well, and 
500 µl of the suspension was immediately transferred to another tube containing 5 µl of 
diethylaminobenzaldehyde (DEAB) reagent in 95% ethanol. The tubes were incubated 
for 45 min at 37°C, following which the cells were centrifuged in cold, and redispersed in 
cold ALDEFLUOR® assay buffer and stored on ice. Cells were then sorted using BD 
FACSVantage (BD Biosciences) cell sorter. Cells incubated with DEAB reagent were 
used to gate for cells having low ALDH level (ALDHlow), and cells to the right of the 
gate were sorted as ALDHhigh population. Around 3 – 4% of MDA-MB-231 cells were 
ALDHhigh. ALDH-sorted cells were subjected to 30 min of magnetic hyperthermia. Cells 
incubated with or without SPIO NP and not exposed to alternating magnetic field were 
used as controls. Treated cells were evaluated for clonogenicty as described above.  
3.2.2.5.4. Tumorigenicity assay 
The study was carried out in compliance with protocol approved by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Female 
BALB/c-nude mice (C.Cg/AnNTac-Foxn1nu NE9; Taconic Farms), four to six weeks of 
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age, were used for the studies. Mice received either 5000 or 50,000 live A549 cells 
(trypan blue exclusion) that were previously subjected to 30 min of magnetic 
hyperthermia. Animals that received similar number of untreated cells or cells treated 
with SPIO NPs but not exposed to alternating magnetic field served as controls. Animals 
were observed once every three days for the appearance of palpable tumors 206. Tumor 
dimensions were also measured using a digital calipers, and the tumor volume (V) was 
calculated using the formula V = 0.5(L × W2), where L and W are the longest and shortest 
diameters, respectively. Development of 100 mm3 tumors or 60 days after cell injection 
(whichever came first) marked the end of the study for each animal. 
3.2.2.6. Cytotoxicity studies 
3.2.2.6.1. Cell death after magnetic hyperthermia 
About 1 million cells were suspended in 500 µl of RPMI (without phenol red and 
with 5% FBS). 500 µl of 5 mg/ml SPIO NP dispersion in the same medium was added to 
the cell suspension placed in an alternating magnetic field (6 kA/m, 386 kHz) for 5, 15 or 
30 min. The cell suspension temperature was carefully maintained between 43 and 46°C 
(Figure 3.1). Cells with or without SPIO NPs and not exposed to alternating magnetic 
field were used as controls. In addition, cells incubated in a water bath at 46°C for 30 
min, with or without SPIO NPs, served as conventional hyperthermia controls. Following 
treatment (after 2 hours), the cells were pelleted down and the amount of lactate 
dehydrogenase (LDH) released by the cells in the supernatant was analyzed. LDH 
released by the untreated control was used to normalize for the background cell death and 
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LDH released by equal number of freeze-thaw lysed cells was used to calculate 100% 
cell death.  
 
 
 
To evaluate the induction of apoptosis by magnetic hyperthermia, treated cells 
were gently dispersed in medium containing 10% FBS, and plated in 6-well plates. After 
another 10 hrs, cells were examined for apoptosis/necrosis by a flow-cytometry-based 
annexin-V FITC/propidium iodide (PI) assay. Briefly, cells were trypsinized and then 
Figure 3.1 Temperature profile during magnetic hyperthermia. Treatment tubes that 
were pre-equilibrated to 37°C were placed in alternating magnetic field and the 
temperature was monitored. The magnetic field was turned off when the temperature 
reached 45.5°C and restarted at 43.5°C to maintain the temperature within a narrow 
range. The duration of magnetic hyperthermia was defined as the period when the 
temperature was between 43 and 46°C. 
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centrifuged at 1000 rpm for 8 min. The cell pellets were stained with FITC-conjugated 
annexin-V and PI according to manufacturer’s instructions (BD Pharmingen™, San Jose, 
CA) and then immediately analyzed using a flow cytometer (BD FACSCalibur™, BD 
Biosciences, San Jose, CA). FITC and PI fluorescence emissions were detected in FL-1 
(515 - 545 nm) and FL-3 (670 long-pass) modes, respectively. Data from at least 10,000 
cells were analyzed using Cyflogic software (Cyflo Ltd., Turku, Finland).  
3.2.2.6.2. Clonogenicity 
 
Clonogenicity was used as a measure of the proliferative potential of cells 
subjected to magnetic hyperthermia 209. Following treatment, 200 live cells (identified by 
trypan blue exclusion assay) from each group were plated in 10 cm culture dish and 
allowed to form colonies. After 2 weeks (about 12 – 15 cell doubling times 210, 211), the 
plates were washed with DPBS and fixed with 5% formalin in DPBS for 3 min. Colonies 
were further washed with DPBS and then stained with 0.05% crystal violet for 30 min. 
Plates were then washed gently with water, air-dried, and the number of colonies formed 
in each treatment groups was counted. Colonies were counted prior to and after washing 
and staining steps to account for the loss of colonies during the processing steps. 
3.2.2.6.3. Instantaneous cell death during magnetic hyperthermia 
Following incubation of cells with SPIO NPs, 2 mM 7-aminoactinomycin-D 
(7AAD), a cell viability stain, was added to the cells prior to exposing them to magnetic 
field. Cells not exposed to alternating magnetic field, with or without SPIO NPs, and 
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cells exposed to 30 min of conventional hyperthermia were used as controls. Following 
treatments, cells were immediately washed by centrifugation, resuspended in RPMI 
(without phenol red) and subjected to flow cytometry. 7AAD fluorescence was detected 
in the FL-3 channel. Data from 20,000 cells in each group were analyzed using Cyflogic 
software. 
3.2.2.7. Reactive oxygen species (ROS) generation after magnetic 
hyperthermia 
Immediately prior to magnetic hyperthermia treatment, 5-(and-6)-chloromethyl-
2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (7.5 µM) and PI 
(10 µM) were added to A549 cell suspension. Cells were subjected to magnetic 
hyperthermia and then to flow cytometric analysis. The deacetylated and oxidized 
product, 2',7'-dichlorofluorescein, formed due to ROS generation in the cells, was 
detected in the FL-1 channel while PI fluorescence was detected in the FL-3 channel.  
To determine the role of ROS in inducing cell death, cells were pretreated with 10 
mM N-acetyl cysteine for 1 hr before adding CM-H2DCFDA and then subjected to 5 min 
of magnetic hyperthermia. Cells treated with 5 mM hydrogen peroxide with and without 
N-acetyl cysteine pretreatment served as additional controls. 
3.2.2.8. Statistical analysis 
Statistical analyses were performed using one-way ANOVA by Bonferroni-Holm 
method for comparison between individual groups. A probability level of P < 0.05 was 
considered significant. 
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3.3. Results  
3.3.1. Characterization of SPIO NPs 
The physico-chemical properties of SPIO NPs used in this study are summarized 
in Table 3.1. The particles were composed of 74 ± 2% w/w iron oxide, coated with 10 ± 
3% w/w myristic acid, and stabilized by 16 ± 2% w/w Pluronic F127. TEM studies 
indicated that the mean Feret’s diameter of the iron oxide core was 12 ± 3 nm (Figure 
3.2A). This result was confirmed by the mean particle size calculated from XRD data (12 
± 1 nm) (Figure 3.3). SPIO NPs had an average hydrodynamic diameter of 185 nm, 
suggesting that particles in aqueous media existed as small aggregates rather than as 
individual SPIO NPs. FTIR spectroscopy showed the presence of characteristic magnetite 
bands at 570 cm-1 and 400 cm-1 and the absence of maghemite bands at 700 cm-1 and 
630-660 cm-1, indicating that the primary form of iron oxide in SPIO NPs was magnetite 
(data not shown) 1. SPIO NPs had a high saturation magnetization of 60.5 emu/g of 
magnetite, with negligible remanence and coercivity, verifying their superparamagnetic 
nature (Figure 3.2B). The heating rate of SPIO NPs was concentration-dependent and 
was similar in both cell culture medium and in agarose gel (Figure 3.2C, D). Based on the 
heating rates, a concentration of 2.5 mg/ml of SPIO NPs (equivalent to 1.85 mg/ml of 
magnetite) was found to be optimal for inducing magnetic hyperthermia in vitro.  
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Table 3.1 : SPIO NP characterization 
Composition 
Form of iron oxide Magnetite 
Iron oxide content 74 ± 1.6 % 
Myristic acid coating 10 ± 2.7 %  
Pluronic F127 coating 16 ± 1.6 %  
Particle size 
Particle size (TEM) 12 ± 3 nm 
Crystallite size (XRD) 12 ± 1 nm 
Hydrodynamic diameter (DLS) 185 nm  
Polydispersity 0.22 
Magnetic parameters 
Saturation magnetization 60.5 emu/g magnetite 
Remanence 1.6 emu/g magnetite 
Coercivity 1.37 Oersted 
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Figure 3.2 Characterization of SPIO NPs. (A) Representative TEM image of SPIO 
NPs. A drop of aqueous NP suspension was placed on a TEM grid and air-dried 
before observing under an electron microscope. Scale bar, 50 nm. (B) Magnetization. 
Magnetization curves were recorded on a vibrating sample magnetometer. The curve 
was normalized to the weight of magnetite added to obtain saturation magnetization 
per gram of magnetite. The sigmoidal curve is characteristic of superparamagnetic 
substances. Heating rates of SPIO NPs dispersed in (C) cell culture medium and 
(D) agarose gel. SPIO NP dispersions in a borosilicate glass tube were placed in an 
alternating magnetic field of 6 kA/m and operating at a frequency of 386 kHz. The 
initial temperature was equilibrated to 37° C, and the temperature of SPIO NP 
dispersion was sampled at 15 second intervals using a fluoroptic probe following the 
application of alternating magnetic field.  
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Figure 3.3 XRD pattern of SPIO NP. The XRD pattern (black) is overlaid on the 
cumulative peak fit data (red) calculated from the summation of the individual peak fit 
based on the pseudo-Voigt function. Blue bars indicate the standard peak profile of 
pure magnetite. 
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3.3.2. Effect of magnetic hyperthermia on CSCs  
3.3.2.1. Side population in A549 cells  
The side population phenotype, characterized by overexpression of efflux 
transporters, is believed to be rich in CSCs 206. Hoechst 33342 is a substrate of both P-
glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), and the assay is 
therefore considered a direct correlate of transporter expression. The difference in the 
fraction of Hoechst 33342-negative cells with and without the dual efflux inhibitor 
tariquidar is considered the side population. Interestingly, magnetic hyperthermia resulted 
in a considerable decrease in the side-population (~12% in magnetic hyperthermia group 
vs. 20% in the non-hyperthermia SPIO NP control) (Figure 3.4A). 
3.3.2.2. Mammosphere assay 
Mammospheres are clusters of mammary tumor cells growing in an anchorage-
independent fashion and have been shown to be a quantitative indicator of the CSC sub-
population 212. We observed a significant reduction (P < 0.01 vs. untreated cells) in 
mammosphere formation in MDA-MB-231 cells following magnetic hyperthermia 
(Figure 3.4B). Untreated cells or cells subjected to conventional hyperthermia formed 
rigid mammospheres, whereas magnetic hyperthermia treated groups formed smaller 
spheres (Figure 3.5). While 5 min and 15 min of magnetic hyperthermia resulted in 63% 
and 90% reduction in mammosphere formation respectively, there was a complete 
absence of mammosphere formation after 30 min of magnetic hyperthermia.  
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Figure 3.4 Effect of magnetic hyperthermia on CSCs. (A) Side population assay. 
Following magnetic hyperthermia, A549 cells were incubated with Hoechst 33342 dye at 
37°C for 90 min followed by flow cytometric analysis of Hoechst 33342 fluorescence in blue 
and red channels. Cells pretreated with tariquidar (a dual P-gp and BCRP efflux inhibitor) 
were used as controls. The flow images shown are representative Hoechst profiles of cells 
treated with SPIO NPS with (left) and without (right) heating. Side population is shown 
circumscribed within the oval area. The average percent (± S.D.) of side population is shown 
for each group, n = 3. (B) Mammosphere formation. After magnetic hyperthermia, 3000 live 
cells (counted by trypan blue exclusion) were plated in ultra-low adhesion 6-well plates with 
mammosphere medium and left undisturbed at 37°C. The number of mammospheres formed 
was counted using a light microscope on day 5 after treatment. Data shown is mean ± S.D., n 
= 3. * P < 0.01 vs. untreated cells. (C) Clonogenicity of ALDHhigh and ALDHlow MDA-MB-
231 cells. MDA-MB-231 cells were sorted based on ALDH enzyme levels and then subjected 
to 30 min of magnetic hyperthermia. Post-treatment, 200 live cells were plated for 
clonogenicity assessment. The graph shows the relative survival fraction compared to 
untreated cells. Data shown is mean ± S.D., n = 3. * P < 0.05; # P < 0.001 vs. untreated cells.  
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Figure 3.5 Microscopic images of mammospheres formed. The images shown are 
representative higher magnification images of mammospheres formed in each 
treatment group referred to in Figure 3.4B. Remaining SPIO aggregates can be seen in 
all groups that were treated with NPs. Scale bar, 100 µm.  
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3.3.2.3. ALDH assay 
High levels of ALDH have been reported for normal and cancer precursor cells 
208,211
. To determine the effect of magnetic hyperthermia on cells with differential ALDH 
expression, MDA-MB-231 cells were sorted based on the overall levels of the ALDH 
enzyme. Clonogenicity studies revealed that both ALDHhigh and ALDHlow cells were 
equally susceptible to magnetic hyperthermia, with a complete absence of colony 
formation following magnetic hyperthermia in either population (Figure 3.4C). Treatment 
with SPIO NP also caused a smaller but significant (p < 0.05) reduction in clonogenicity 
of both ALDHhigh and ALDHlow cells. 
3.3.2.4. Tumorigenicity assay 
A characteristic feature of CSCs is their ability to initiate a tumor in 
xenotransplantation assays 213. In vivo tumor initiation study performed in nude mice 
showed a significant delay in tumor initiation with magnetic hyperthermia-treated cells 
compared to the corresponding controls. While most control animals developed a tumor 
within 15 days of cell injection, the first tumor appeared in magnetic hyperthermia-
treated groups at 21 days (50,000 cell injection) or 36 days (5000 cell injection) post-
injection (Figure 3.6A). Furthermore, 40% of the animals that received magnetic 
hyperthermia-treated tumor cells did not develop tumors even at 60 days post cell 
injection (Figure 3.6B). 
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Figure 3.6 In vivo tumorigenicity of magnetic hyperthermia treated cells. A549 cells 
subjected to magnetic hyperthermia were injected subcutaneously into BALB-nude 
mice at a cell density of 5000 or 50,000 live cells per animal. Untreated cells or cells 
incubated with SPIO NPs but not exposed to alternating magnetic field were used as 
controls. A tumor size of 100 mm3 or 60 days post cell injection (whichever came 
first) marked the end of the study. (A) Percent tumor-free animals and (B) average 
tumor volumes plotted as a function of days after cell injection. Data shown is mean ± 
S.D., n = 5. 
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3.3.3. Cell kill after magnetic hyperthermia  
LDH released by cells was used as a quantitative indicator of cell death 214. 
Magnetic hyperthermia effectively induced cell death in both A549 and MDA-MB-231 
cells (Figure 3.7A), and the efficacy of cell kill was found to increase with increasing 
duration of exposure to magnetic hyperthermia. Prolonged (30 min) treatment resulted in 
88% and 90% cell death in A549 and MDA-MB-231 cells, respectively. Conventional 
hyperthermia for 30 min was much less effective in killing cancer cells compared to 
magnetic hyperthermia. 
Induction of apoptosis after magnetic hyperthermia was determined using 
Annexin-FITC/PI assay. The overall percent of healthy cells decreased with increasing 
duration of treatment (Table 3.2). The proportion of early apoptotic cells was higher for 5 
and 15 min magnetic hyperthermia but was lower for 30 min treatment compared to SPIO 
NP-treated cells. However, there was a higher percent of late apoptotic/necrotic cells in 
the group exposed to 30 min of magnetic hyperthermia. Conventional hyperthermia was 
much less effective than magnetic hyperthermia in inducing apoptosis (2% early 
apoptotic cells and 6% late apoptotic cells).  
Clonogenicity assay showed that magnetic hyperthermia resulted in a decrease in 
the proliferative ability and survival of both A549 and MDA-MB-231 cells (Figure 3.7B). 
Notably, cells subjected to 30 min of magnetic hyperthermia did not form any colonies in 
either cell line. 
Instantaneous 7AAD uptake was used as a measure of acute cell kill during 
magnetic hyperthermia. As can be seen from Figure 3.8, magnetic hyperthermia induced 
instantaneous 7AAD uptake in the treated cells. The 7AAD profile (30%, 47% and 73% 
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after 5 min, 15 min and 30 min of magnetic hyperthermia, respectively) was comparable 
to the LDH profile (Figure 3.7A). No significant 7AAD uptake was observed in cells 
exposed to conventional hyperthermia.  
 
Table 3.2 : Induction of apoptosis and necrosis determined by annexin-V/PI assay 
 
 (PI-/A-) 
(Healthy) 
(PI-/A+)  
(Early 
apoptotic) 
 (PI+/A+)  
(Late 
apoptotic) 
(PI+/A-)  
(Necrotic) 
Untreated cells
 
97
 
1
 
1
 
0.4
 
SPIO NP
 
97
 
0.6
 
2
 
0.7
 
5 min magnetic 
hyperthermia
 
92
 
2
 
6
 
0.4
 
15 min magnetic 
hyperthermia
 
81
 
3
 
14
 
2
 
30 min magnetic 
hyperthermia
 
62
 
2
 
33
 
3
 
Conventional 
hyperthermia
 
93
 
2
 
6
 
0.2
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Figure 3.7 Effect of magnetic hyperthermia on tumor cell kill. (A) LDH release. 
Cells were subjected to magnetic hyperthermia for 5, 15 or 30 min, following which 
the supernatant medium was assayed for the amount of LDH released. SPIO NP-
treated cells (without exposure to AMF) and cells subjected to 30 min of conventional 
hyperthermia at 46 °C were used as controls. Equal numbers of freeze-thaw lysed cells 
were used to determine LDH release from 100% cell death while untreated cells were 
used to determine background LDH release. Data shown is mean ± S.D., n = 3. * P < 
0.05; # P < 0.01 vs. untreated cells. (B) Clonogenicity. About 200 live cells from each 
treatment group were plated in a 10 cm tissue culture plate and observed for colony 
formation. The number of colonies formed was counted 2 weeks later. Data shown is 
mean ± S.D., n = 3. All treatments resulted in statistical significant (P < 0.01) decrease 
in surviving fraction.  
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3.3.4. ROS generation during magnetic hyperthermia 
ROS generation increased with increased duration of magnetic hyperthermia 
(Figure 3.9). Conventional hyperthermia did not affect ROS levels compared to untreated 
cells. Following magnetic hyperthermia, ROS positive population appeared to become 
necrotic with time, as evidenced by the migration of ROShigh/PIlow population to 
ROShigh/PIhigh quadrant (Figure 3.10). Addition of N-acetyl cysteine, an antioxidant 215, 
inhibited ROS generation (not shown) and decreased the fraction of cells becoming PI 
Figure 3.8 Instantaneous 7AAD uptake during magnetic hyperthermia. 7AAD was 
added to each treatment tube immediately prior to magnetic hyperthermia. After 
treatment, the cells were washed to eliminate excess 7AAD and subjected to flow 
cytometric analysis. Data shown is mean ± S.D., n = 3. All hyperthermia treatments 
resulted in statistical significant (P < 0.01) increase in 7AAD uptake. 
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positive without affecting the initial population of cells that took up PI instantaneously 
(Figure 3.11). Interestingly, though ROS production and PI uptake by cells that 
underwent conventional hyperthermia was comparable to that by untreated cells, cells 
subjected to conventional hyperthermia in the presence of SPIO NPs demonstrated 
greater ROS production compared to those that received only SPIO NPs (Figure 3.12). 
 
 
 
Figure 3.9 ROS generation immediately after treatment. CM- H2DCFDA was added 
to A549 cells immediately before exposure to alternating magnetic field, followed by 
flow cytometric analysis to determine ROS levels. The graph shows the effect of 
treatments on geometric mean intensity of fluorescence, an indicator of ROS levels in 
the cells. Data shown is mean ± S.D., n = 3. All treatments resulted in statistical 
significant (P < 0.01) increase in the geometric mean intensity of ROS fluorescence. 
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Figure 3.10 Kinetic study to monitor ROS levels and PI uptake by cells subjected to 
magnetic hyperthermia. Cells were first treated with CM- H2DCFDA and PI and then 
subjected to 5 min of magnetic hyperthermia. Fluorescence from ROS generation and 
PI uptake by the cells were monitored by flow cytometry. The change in the flow 
profile of untreated (top), cells treated with SPIO NPs (middle) and cells treated with 
magnetic hyperthermia (bottom) are shown at different times after treatment.  
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Figure 3.11 Effect of ROS scavenging on PI uptake by magnetic hyperthermia treated 
cells. Prior to SPIO NP or CM-H2DCFDA addition and exposure to alternating 
magnetic field, cells were pretreated with N-acetyl cysteine (NAC) to scavenge free 
radicals. The percent of PI positive cells at different time point are plotted for the 
treatment groups. Data shown is mean ± S.D., n = 3. * P < 0.001 vs. all other groups. 
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Figure 3.12 ROS generation and PI uptake by cells treated with conventional 
hyperthermia in the presence of SPIO nanoparticles. CM-H2DCFDA and PI was 
added to cells immediately before hyperthermia treatment. Fluorescence from ROS 
generation and PI uptake by the cells were measured 2 hrs after treatment by flow 
cytometry. The graph plots PI positive cells (light gray bars) in the primary axis and 
the geometric mean intensity (which is proportional to ROS levels in cells) (dark gray 
bars) in the secondary axis. An increase in ROS levels and cell death (PI uptake) is 
observed in cells incubated with SPIO NP while being subjected to conventional 
hyperthermia. Data shown is mean ± S.D., n = 3. All treatments resulted in statistical 
significant (P < 0.01) difference in the geometric mean intensity of ROS fluorescence 
and the percent PI positive cells compared to untreated cells.  
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3.4. Discussion 
 Magnetic hyperthermia, a technique involving the use of SPIO NPs subjected to 
AMF to generate heat 58, has been studied for treating tumors as early as 1957 59. The 
main advantage of magnetic hyperthermia is that the heating rate can be well controlled 
by adjusting particle size and shape of SPIO NPs as well as by modulating the properties 
of the alternating magnetic field 60. There are several magnetic materials that can be used 
for inducing magnetic hyperthermia. However, most studies have focused on magnetic 
iron oxides, Fe3O4 (magnetite) 61,62 and γ –Fe2O3 (maghemite) 63,64, which have been 
proved to be well tolerated in clinical studies 65. The core size of SPIO NPs dictates the 
primary mechanism of heat generation – Brownian relaxation and/or Néel relaxation 68,67. 
The predominant mechanism of heat generation by 12 nm SPIO NPs used in our studies 
is through Néel relaxation, a mechanism of heat generation unaffected by suspending 
medium viscosity. This was confirmed from the similar heating rates observed for SPIO 
NPs in liquid and gel media. This data suggests that heat production by these particles 
will not likely be affected by the presence of dense extracellular matrix found in solid 
tumors 216. Additionally, higher saturation magnetization of magnetic substances is more 
desirable, because this translates to higher heating rate per unit mass. SPIO NPs used in 
our studies were composed of magnetite, which possesses higher saturation 
magnetization than maghemite 217. Optimum size and properties of synthesized SPIO 
NPs, along with their high saturation magnetization and iron content, allowed for 
effective induction of magnetic hyperthermia in our studies.  
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A number of preclinical studies have demonstrated the potential use of magnetic 
hyperthermia as an effective anticancer treatment modality 58. In addition, magnetic 
hyperthermia is in clinical trials for different cancers 199,218. However, there are no reports 
on the effect of magnetic hyperthermia on CSCs, a sub-population that is thought to be 
responsible for tumor drug resistance and relapse 219. Since no single assay is 
confirmatory with regard to the effect of treatments on CSCs, we evaluated the effect of 
magnetic hyperthermia on multiple biomarkers and functional properties of CSCs. 
Hoechst 33342 efflux 206 and ALDH 220 assays are functional assays identifying CSC-rich 
population, while mammosphere formation and tumorigenicity assays are based on the 
growth and proliferative properties unique to CSCs 221. All of these assays indicated that 
magnetic hyperthermia reduced or, in some cases, eliminated the CSC sub-population in 
treated cells.  
Magnetic hyperthermia was effective in reducing CSC population in both long-
term assays such as mammosphere formation as well as in short-term studies such as side 
population assay. The short-term effects of magnetic hyperthermia could be attributed to 
the induction of acute cell death, which was evident from high LDH release immediately 
after the treatment. The increased number of 7AAD positive cells immediately after 
treatment further points to the possibility of acute necrosis induced by magnetic 
hyperthermia. Lack of significant acute cell kill with conventional hyperthermia suggests 
that necrosis brought about by magnetic hyperthermia was likely temperature-
independent. CSCs have been shown to be resistant to induction of apoptosis 222, a slow 
programmed process of cell death. Necrosis is a more violent and acute cell death, most 
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often mediated by mechanical damage to cell membrane and/or other vital cellular 
organelles 223. If magnetic hyperthermia indeed caused necrosis, it is unlikely that CSCs 
will have resistance mechanisms to tolerate this acute cell death pathway 213.  
 Exposure of cells to 30 min of magnetic hyperthermia resulted in the induction of 
apoptosis/necrosis in only about 35% of cells 20 hrs after treatment, suggesting that a 
majority of the cells are viable and healthy. However, these cells did not form any 
colonies in the clonogenicity assay. This implies that in addition to acute necrosis, there 
is a pronounced long-term effect of magnetic hyperthermia on CSCs. A mechanism 
postulated for the resistance of CSCs against DNA damage is decreased basal levels of 
ROS generation in CSCs 194. Since SPIO NPs have been reported to induce ROS 224, we 
investigated ROS generation as a possible mechanism of cell kill with magnetic 
hyperthermia. Immediately after magnetic hyperthermia, ROS levels were higher than in 
controls, and this appeared to be followed by a slow increase in the number of dying 
cells. Inhibition of ROS generation using an antioxidant suppressed this transition. These 
results suggest that magnetic hyperthermia induces ROS generation, which results in 
additional cell death after some latency. Similar increase in ROS production and cell 
death was observed in cells incubated with SPIO NPs and subjected to conventional 
hyperthermia but not in those subjected to either conventional hyperthermia alone or 
SPIO NP treatment alone. Overall, our studies suggest that ROS generation by magnetic 
hyperthermia is mediated by the presence of SPIO NPs and is amplified by higher 
temperatures. One possibility is that SPIO NPs generate ROS, which would normally be 
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scavenged efficiently by CSCs 225; however, generation of heat could decrease the ability 
of CSCs to scavenge ROS and thereby increases their susceptibility to ROS. 
3.5. Conclusions 
CSCs are considered to play important roles in tumor drug resistance and 
recurrence. Our studies show that CSCs and non-CSCs are equally susceptible to cell 
death induced by magnetic hyperthermia. Further, magnetic hyperthermia induces both 
acute necrosis and a slower, ROS-mediated cell-death in treated cells. Some of the cell 
kill events appear to be temperature-independent, although elevated temperatures appear 
to amplify those effects. Overall, these results suggest the potential for effective CSC 
eradication by magnetic hyperthermia. Future studies will investigate the effect of 
magnetic hyperthermia on in vivo tumor growth and tumor recurrence. 
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4.1. Introduction 
Lung cancer is the leading cause of cancer-related deaths in the United States 2. 
Surgical resection is the primary choice of treatment, followed by radiation and/or 
chemotherapy 226. Despite earlier diagnosis and the availability of new molecularly-
targeted drugs, the five-year survival rate has not changed significantly over the last 
several years 2. Metastatic and locally advanced disease stages are not amenable to 
surgical resection, and importantly, a majority of patients who undergo surgery 
eventually experience relapse 227-229. Poor response rates and survival with current 
treatments clearly indicate the urgent need for developing an effective means to treat non-
small cell lung cancer.  
Magnetic hyperthermia is a novel non-invasive approach for tumor ablation and is 
based on heat generation by magnetic materials, such as superparamagnetic iron oxide 
(SPIO) nanoparticles, when subjected to an alternating magnetic field (AMF) 156,157. 
Depending on the size of SPIO nanoparticles and the frequency of AMF, heat is 
generated through either Néel or Brownian relaxation. The heat generated dissipates over 
short distances due to the high thermal conductivity of water and can, therefore, be used 
for highly focused heating 58,158. However, inadequate delivery of magnetic nanoparticles 
to tumor cells can result in sub-lethal temperature change and induction of resistance 230. 
Additionally, non-targeted delivery of these particles to the healthy tissues can result in 
heat damage to normal tissues.  
In our studies, we developed epidermal growth factor receptor (EGFR)-targeted, 
inhalable SPIO nanoparticles for magnetic hyperthermia of non-small cell lung cancer 
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(NSCLC). EGFR overexpression has been observed in as many as 70% of NSCLC 
patients 140-142, in whom EGFR expression is elevated in epithelial sites within tumors 
than in sites adjacent to and distant from tumors. We examined the effect of EGFR 
targeting on accumulation and retention of inhaled SPIO nanoparticles in the tumor tissue 
and the effect of targeted magnetic hyperthermia therapy on tumor growth in an 
orthotopic lung tumor model.  
 
4.2. Materials and Methods 
4.2.1. Materials 
Ferrous chloride tetrahydrate, ferric chloride hexahydrate, myristic acid, Pluronic 
F127, ascorbic acid, potassium hydroxide, 1,10 phenanthroline and sodium acetate were 
purchased from Sigma (St. Louis, MO). Penicillin/streptomycin, fetal bovine serum, 
RPMI 1640, Dulbecco’s phosphate buffered saline, F-12K (Kaighn’s modification) and 
trypsin-EDTA solution were obtained from Invitrogen Corporation (Carlsbad, CA).  
4.2.2. Methods 
4.2.2.1. Synthesis of carboxy-terminated pluronic F127 (CTP) 
The synthesis of CTP involved the use of an acid anhydride, which is highly 
susceptible to the presence of moisture. Hence, all the solvents used in the reaction were 
anhydrous and the reaction environment was maintained as dry as possible. A mass of 2 
grams of pluronic F127 was dissolved in 40 ml of anhydrous tetrahydrofuran. To the 
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solution, 100 mg of 4-dimethylaminopyridine, 72 µl of triethylamine and 800 mg of 
succinic anhydride were added, and the flask was sealed immediately. The mixture was 
stirred at room temperature for 48 hours under nitrogen atmosphere. After 2 days, the 
volatile solvent was removed by rotary evaporation, and the dry residue was dissolved in 
40 ml of carbon tetrachloride. The undissolved, unconjugated succinic anhydride was 
removed by filtration. The remaining polymer solution was concentrated using a rotary 
evaporator, and CTP was precipitated by drop-wise addition of the solution in cold, dry 
diethyl ether 231. The residue was filtered, dried in a vacuum oven at 40° C overnight and 
analyzed by proton NMR. The final yield of CTP was 1.74 g. 
Completion of the reaction was confirmed by NMR. Around 25 mg of CTP was 
dissolved in 750 µl of deuterated water and analyzed using a 400 MHz NMR. The NMR 
spectrum of unmodified pluronic F127 was also obtained for comparison.  
4.2.2.2. Conjugation of EGFR-targeting peptide or the isotype scrambled 
peptide to CTP 
A mass of 42 mg of CTP was dispersed in 1.8 ml deionized water. To this 
solution, 10 mg of N-(3-Dimethyl aminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC) and 14 mg of N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (each 
dissolved in 100 µl deionized water) were added and then stirred for 15 minutes at room 
temperature. The pH of the reaction mixture was 6 -7. The excess unreacted EDC was 
quenched by the addition of β-mercaptoethanol at a final concentration of 130 mM. 10 
mg of either the EGFR targeted peptide (YHWYGYTPQNVI) or the scrambled peptide 
(HWPYAHPTHPSW) 143 was dissolved in 200 µl of deionized water and added to the 
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reaction mixture. 245 µl of 10X PBS was added to buffer the reaction and the pH was 
maintained around 7 – 8. The reaction mixture was stirred overnight at room temperature 
232
. The solution was dialyzed against water for 48 hours using a 3500 Da molecular 
weight cutoff Slide-a-lyzer® dialysis cassette, and the final solution was lyophilized 
(Labconco, FreeZone 4.5, Kansas City, MO). 
Conjugation of the peptides to CTP was confirmed by NMR. Around 25 mg of 
the conjugate was dissolved in 750 µl of deuterated water and analyzed by a 400 MHz 
NMR. NMR spectra of the free peptides were used for identification of the resonances 
corresponding to the peptide. 
4.2.2.3. Synthesis of water-dispersible SPIO nanoparticles 
SPIO nanoparticles were synthesized from iron chlorides by the addition of a 
strong base, followed by coating with a fatty acid to prevent oxidation and then with a 
surfactant to form a stable aqueous dispersion 204. Specifically, 0.82 g of ferric chloride 
hexahydrate and 0.33 g of ferrous chloride tetrahydrate were dissolved in 30 ml of 
degassed and nitrogen-purged water, and 3 ml of 5 M ammonium hydroxide was added 
drop-wise to this solution, which was then stirred for 30 minutes. The resulting iron oxide 
nanoparticles were washed three times with nitrogen-purged water, sonicated in a water 
bath sonicator for 2 min, and then heated to 80°C. About 100 mg of myristic acid was 
added to the heated mixture and stirred for another 30 min. Excess myristic acid was 
removed by two washes with ethanol, followed by two additional washes with water to 
remove excess ethanol. Each wash was followed by magnetic separation of nanoparticles. 
Myristic acid coated particles were then suspended in 30 ml water using a water-bath 
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sonicator. Targeted or scrambled peptide conjugated pluronic, equivalent to 5% surface 
coverage of the peptide (5.5 mg and 11.7 mg of targeted and scrambled peptides, 
respectively), was mixed with pluronic F127 to yield a total mass of 100 mg, which was 
then added to the suspension and sonicated in a bath sonicator for 1 hour. Every step of 
the synthesis was conducted carefully to minimize exposure to atmospheric oxygen. 
4.2.2.4. Characterization of SPIO nanoparticles 
The average hydrodynamic diameter of SPIO nanoparticles was determined by 
dynamic light scattering. About 1 mg of SPIO nanoparticles was dispersed in 2 ml of 
deionized water by sonication and the dispersion was subjected to particle size analysis 
using a Delsa™ Nano C Particle Analyzer (Beckman, Brea, CA). The measurement was 
performed at 25°C and at a 165° scattering angle. Mean hydrodynamic diameter was 
calculated based on size distribution by weight, assuming a lognormal distribution. Five 
individual size measurement runs were performed, with each run recording 150 size 
events. 
The iron content of the SPIO nanoparticles was measured using the 1,10 
phenanthroline-based iron assay 160. SPIO nanoparticles were first dissolved in12 N 
hydrochloric acid. The solution was then diluted with distilled water to obtain a final acid 
concentration of 0.2 N. To the acid solution of SPIO nanoparticles, 10 mg/ml ascorbic 
acid, 1.2 mg/ml 1,10 phenanthroline, 22.4 mg/ml potassium hydroxide and 123 mg/ml 
sodium acetate were added in a volume ratio of 1:1:1:1:5. Absorbance of the resultant 
solution was measured at 490 nm using a microplate reader (ELx800 Absorbance 
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Microplate Reader, Biotek, Winooski, VT). Ferric chloride (hexahydrate) solutions in 0.2 
N hydrochloric acid was used as a standard.  
4.2.2.5. Magnetic heating rate 
SPIO nanoparticles were dispersed in 1 ml of Hank’s F-12K medium in 10 mm X 
75 mm disposable borosilicate glass cell culture tubes. Magnetic heating was performed 
using an induction heating system (1 kW Hotshot, Ameritherm Inc., Scottsville, NY) by 
placing the suspension at the center of a multiturn copper coil that generated AMF 
(nominal magnetic field strength of 6 kA/m and frequency of 386 kHz). The temperature 
change was measured using a fluoroptic® probe (Lumasense Technologies, Santa Clara, 
CA) at five second intervals. Samples were equilibrated to 37 °C using a water-bath 
before exposure to the field.  
4.2.2.6. Aerosol generation and characterization  
Aerosolization of SPIO nanoparticles was achieved by ultrasonic atomization 233. 
A Pyrex glass baffle was constructed in-house and placed in a water bath, directly over a 
1.7 MHz ultrasonic transducer 234. About 13 ml of SPIO nanoparticle dispersion in 40% 
ethanol, containing 8 mg magnetite per ml was loaded into the baffle. Compressed air 
directed into the baffle at a flow rate of 0.5 L/min (as measured by an inline flow meter) 
entrained the aerosol droplets containing the SPIO nanoparticle dispersion and carried the 
particles into a subsequent drying assembly. The iron oxide output in the aerosol was 
measured by collecting the aerosolized and dried SPIO particles for a predetermined 
period of time on Whatman quartz microfiber filters suitable for air sampling 235. The 
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filters were assayed using the above procedure and the iron oxide output rate was 
calculated as iron oxide amount collected per unit time.  
The aerosol particle size distribution was determined with a Mercer style seven-
stage Intox cascade impactor operating at a sample flow rate of 0.5 L/min. The aerosol 
generated was passed through a heated drying column before passing through the cascade 
impactor. Aerosol particles deposited at each stage of the cascade impactor was collected 
and analyzed by iron assay to obtain the particle size distribution. The mass median 
aerodynamic diameter (MMAD) and associated geometric standard deviation (GSD) 
were calculated from linear regression of an X– probability plot of the cumulative 
undersized mass as a function of logarithm of the impactor stage cutoff diameter using 
OriginPro 8 software (OriginLab Corporation, Northampton, MA) 235.  
4.2.2.7. Cell culture studies 
 A549 (human lung adenocarcinoma) and A549-Luc (luciferase-transfected A549) 
cells were used in the study. Both cell lines were propagated using F-12K medium 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic solution and 
maintained at 37 °C and in 5% carbon dioxide.  
4.2.2.8. Demonstration of role of EGFR in tumor cell uptake of functionalized 
nanoparticles 
A549 cells were plated in a 6-well plate 4 hours before the start of the study. Cells 
were washed with phosphate buffered saline (PBS) to remove non-adherent cells and 1 
mg (magnetite equivalent) of targeted SPIO particles, scrambled peptide-conjugated 
particles, particles without any peptide, or targeted particles with excess free targeting 
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peptide were added to the cells in a total volume of 2 ml of cell culture medium 
containing 5% FBS. The plates were incubated on ice for 30 minutes, washed thrice with 
PBS and incubated at 37°C for an additional 45 minutes. At the end of the incubation, 
cells were lysed with 400 µl of RIPA buffer and assayed for total cell protein content and 
iron content 160 (by iron assay procedure described before).  
To evaluate EGFR targeting on the effectiveness of magnetic hyperthermia, 
plated A549 cells were incubated with targeted or non-targeted particles for 30 minutes at 
4°C, washed three times with PBS, incubated at 37°C for 45 minutes and then subjected 
to AMF (6 kA/m at 386 kHz frequency). Following AMF exposure, 10 µM propidium 
iodide was added to the cells and observed under a fluorescent microscope immediately 
and at 24 hrs after AMF exposure.  
4.2.2.9. Orthotopic lung tumor model 
All animal studies were carried out in compliance with protocol approved by the 
Institutional Animal Care and Use Committee at the University of Minnesota. Female 
Fox Chase SCID® Beige mice (CB17.Cg-PrkdcscidLystbg-J/Crl) four to five weeks of age, 
were obtained from Charles River Laboratories. 
 A mouse orthotopic lung tumor model 236 was used in the studies. Lung tumor 
cells that have been stably transfected with fire-fly luciferase were used to facilitate the 
visualization of tumor cells in live animals using bioluminescence imaging. A549-luc-C8 
Bioware® Cell Line (Caliper Lifesciences) is a luciferase expressing cell line derived 
from A549 human lung squamous carcinoma cells by stable transfection of the North 
American Firefly Luciferase gene expressed from the CMV promoter. Intravenous 
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injection of 1 X 106 A549-luc-C8 cells led to detectable increase in bioluminescence in 
the lungs by 2 weeks.  
4.2.2.10. Lung delivery of SPIO nanoparticles 
4.2.2.10.1. Tracheal instillation 
The mice were anesthetized and placed on a rodent intubation stand, supported by 
their incisors. The tongue was rolled out using a sterile cotton swab and held between the 
fingers. A fiber-optic light and stylus (BioLite, BioTex, Inc., TX) connected to an 
endotracheal tube was used to visualize the tracheal opening and to carefully insert the 
attached endotracheal tube into the trachea. An inflation bulb was used to confirm the 
proper insertion of the endotracheal tube by monitoring the inflation of the thoracic 
region on gently pushing in air through the tube. Targeted or non-targeted SPIO particles 
(50 µl, 10 mg/ml iron oxide equivalent) were instilled through the endotracheal tube. The 
mice were kept upright for a minute to prevent back-flow of the liquid and then placed on 
a heating pad to assist in faster recovery from anesthesia 237. 
4.2.2.10.2. Inhalation 
The aerosol was generated as described above, but the dried SPIO aerosols were 
directed through the drying assembly into an animal chamber, which was comprised of a 
4-port double-walled chamber. The dried aerosol stream entered the top inlet into a 
stirred chamber. The animals were placed into each port with their nose exposed to the 
aerosol stream in the stirred chamber. The exhaust tube was connected to the space 
between the two walls, thus ensuring that the mice underwent a “nose-only” exposure for 
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30 minutes. Filter collections were made three times both before and after the exposure to 
measure the aerosol output. The aerosol stream was also passed through a 7-stage Intox 
cascade impactor before each exposure to determine the aerosol particle size distribution 
(MMAD and GSD) 235.  
4.2.2.11. Distribution of SPIO nanoparticles following instillation and 
inhalation delivery 
Targeted or scrambled peptide conjugated SPIO nanoparticles were administered 
to tumor bearing animals (n = 6 per time point per group) by the two routes of 
administration described above. The animals were euthanized at 1 hour, 1 day or 1 week 
after SPIO administration. The lungs, liver, spleen, kidney, heart, stomach and blood 
were collected to analyze the distribution of SPIO particles. Additionally, lungs of treated 
animals were also sectioned, stained with hematoxylin and eosin (H & E staining) and 
Prussian blue (for iron) 238 and imaged after the last time point to visualize the 
distribution of SPIO particles. Basal level of iron in each organ was determined in six 
healthy mice.  
4.2.2.12. In vivo efficacy of targeted magnetic hyperthermia after inhalation 
delivery of SPIO nanoparticles 
Fox Chase SCID® Beige mice were injected A549-luc cells intravenously to 
facilitate the development of tumors in the lungs. Once the lung bioluminescence reached 
about 0.5 X 106 photons/sec, animals were administered SPIO nanoparticles by 
inhalation. After 7 days, some of the treated animals were subjected to 30 minutes of 
magnetic hyperthermia. Untreated animals and animals receiving the particles without 
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exposure to AMF served as controls. Lung bioluminescence was monitored three times 
weekly for 4 weeks. At the end of the study, animals were euthanized, and the lungs and 
trachea were removed and weighed. Assuming little variability between the lung weights 
of individual mice, the differences in lung weights were attributed to the variable mass of 
lung tumors.  
4.2.2.13. Statistical analysis 
Statistical analyses were performed using one-way ANOVA, followed by 
Bonferroni-Holm method for comparison between individual groups. A probability level 
of P < 0.05 was considered significant. 
 
4.3. Results  
4.3.1. Characterization of inhalable SPIO nanoparticles 
Conversion of the hydroxyl end group of pluronic F127 into a carboxyl group was 
confirmed using NMR spectroscopy and the conversion efficiency was almost 100% 
(Figure 4.1). Presence of targeted or scrambled peptides could be detected in the NMR 
spectra of the modified polymer (Figure 4.1). The conjugation efficiency of EGFR-
targeted peptide and scrambled peptide to CTP was 90.4 ± 10.5% and 42.8 ± 4.6 % 
respectively. SPIO nanoparticles were composed of 74 ± 2% w/w iron oxide, coated with 
10 ± 3% w/w myristic acid, and stabilized by 16 ± 2% w/w Pluronic f127. The 
hydrodynamic diameter of unconjugated (pluronic COOH terminated) SPIO 
nanoparticles was 309 ± 24 nm while that of targeted peptide and scrambled peptide 
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conjugated particles were 369 ± 34 nm and 365 ± 45 nm, respectively. The heating rate of 
SPIO nanoparticles was concentration-dependent, and was similar for both targeted and 
non-targeted SPIO nanoparticles (Figure 4.2). 
 
 
Figure 4.1 NMR spectra of modified pluronic f127. Pluronic F127 has a characteristic 
NMR peak at 1.02 ppm and multiple peaks between 3 and 4 ppm. Conjugation of 
carboxy end group can be detected by the appearance of new peaks at 2.6 and around 
4.2 ppm (solid box). NMR spectrum of the EGFR targeting peptide is different from 
the scrambled peptide with the most visible difference between 6 – 9 ppm. Peptide 
conjugation to the carboxy terminated pluronic (CTP) can be verified from the 
presence of both carboxy modification peaks (solid box) and EGFR targeting peptide 
(dotted box) or scrambled peptide (dashed box) peaks. 
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4.3.2. In vitro cell uptake and cell kill efficiency of targeted SPIO 
nanoparticles 
Non-specific uptake of SPIO nanoparticles in A549 cells was determined as a 
function of time of incubation, concentration of serum in the culture medium and the 
incubation temperature. From these studies, an incubation time of 30 minutes and low 
Figure 4.2 Heating rates of targeted and non-targeted SPIO nanoparticles. SPIO 
nanoparticles dispersions were placed in an alternating magnetic field of 6 kA/m and 
operating at a frequency of 386 kHz. The initial temperature was equilibrated to 37°C, 
and the temperature of SPIO NP dispersion was measured at 10 second intervals using 
a fluoroptic probe following the application of alternating magnetic field. 
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serum concentration were found to be optimal for minimizing the non-specific uptake of 
SPIO nanoparticles (Figure 4.3). Using these optimized parameters, an in vitro study was 
performed to determine the effect of EGFR targeting on cellular uptake of SPIO 
nanoparticles. Nanoparticle uptake into cells was 4.5-fold higher for the EGFR targeted 
formulation than that for the non-targeted control. Conjugation of scrambled peptide did 
not result in enhancement of particle uptake into cells, and the presence of excess 
targeting ligand decreased the cellular uptake of targeted nanoparticles, showing the 
specific role of EGFR in tumor cell uptake of targeted nanoparticles (Figure 4.4).  
 
 
Figure 4.3 Non-specific uptake of SPIO nanoparticles by A549 cells. SPIO 
nanoparticles were incubated with A549 cells in medium containing 2.5% or 7.5% 
FBS at 4°C or 37°C for different durations. SPIO nanoparticle free cells were 
separated from the particle loaded cells by magnetic separation and assayed by MTS 
to determine the relative percent of particle free cells. 
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To determine the effect of EGFR targeting on the effectiveness of magnetic 
hyperthermia, plated A549 cells were incubated with targeted or non-targeted SPIO 
nanoparticles, washed and subjected to AMF. Enhanced cellular accumulation of EGFR 
targeted SPIO nanoparticles could be visualized under the microscope as dark spots on 
the cells (Figure 4.5). Magnetic hyperthermia with targeted nanoparticles resulted in 
Figure 4.4 In vitro cell uptake study. SPIO nanoparticles bearing EGFR targeting 
peptide, scrambled peptide or no peptide on their surface were incubated with A549 
cells at 4°C for 30 minutes, washed with PBS and further incubated at 37°C for 45 
minutes. The specific role of EGFR in enhanced accumulation was confirmed by 
adding excess EGFR targeting peptide to competitively inhibit adhesion of targeted 
SPIO nanoparticles onto the cells. Iron content of the lysed cells were used to estimate 
cell uptake of SPIO nanoparticles. n = 3. * p<0.05. 
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greater number of cells taking up propidium iodide, indicating enhanced cell death with 
targeted SPIO nanoparticles (Figure 4.5). 
 
 
Figure 4.5 Effect of targeted magnetic hyperthermia on in vitro cell kill. Plated A549 
cells were incubated with (A) no particles, (B) targeted or (C) non-targeted SPIO 
nanoparticles (similar to Figure 4.4) and subjected to magnetic hyperthermia (MH) for 30 
min. PI was added immediately before MH treatment and the cells were imaged during 
different interval. The top pictures in each subpanel are the phase contrast microscopic image 
and the lower pictures are fluorescent microscopic images of PI positive cells. The cells in (B) 
and (C) were imaged before MH (left) (after particle incubation), 2 hours after MH (middle) 
and 24 hours after MH (right). Enhanced cellular concentration of SPIO nanoparticles (black 
dots in phase contrast mages) and increased PI positive population in EGFR targeted MH 
indicates the effectiveness of EGFR targeting on MH mediated cell kill.  
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4.3.3. In vivo lung deposition and retention after inhalation delivery  
Ultrasonic atomization of SPIO nanoparticle dispersions resulted in aerosols with 
a MMAD of 1.1 ± 0.1 µm and GSD of 1.9 ± 0.1 (Figure 4.6). The iron oxide output rate 
was determined to be 270 ± 70 µg/min. The high iron oxide output and the MMAD size 
range point to the possibility of a high deposition of these aerosol particles in the mouse 
lung even with a relatively short exposure time. 
 
 
Following aerosol exposure, iron oxide concentration in the lungs at 1 hour 
(Figure 4.7) was similar for targeted and non-targeted SPIO nanoparticles in tumor 
bearing lungs as well as for blank SPIO particles in healthy lungs, showing that the 
Figure 4.6 Inhalable SPIO particle aerodynamic size distribution. SPIO nanoparticle 
suspension was atomized by ultrasonic atomization technique, dried and passed 
through a seven stage cascade impactor. The mass of iron oxide deposited in stage was 
used to calculate the MMAD and GSD of the aerosol formulation. 
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presence of tumor did not affect the total deposition of particles. It also suggested that 
targeting does not affect the lung concentration immediately after the administration of 
particles. However, one week following inhalation, the lung concentration of non-
targeted particles decreased while the level of targeted particles was almost constant, 
demonstrating the effectiveness of EGFR targeting in improving particle retention within 
tumor-bearing lungs. 
 
 
Figure 4.7 In vivo lung deposition and retention of SPIO nanoparticles after 
inhalation delivery. Healthy or A549 orthotopic tumor bearing mice were allowed to 
inhale the targeted or non-targeted SPIO nanoparticles for 30 minutes. The animals 
were euthanized 1 hour and 1 week after inhalation delivery and the lungs were 
assayed for their iron content. n = 4. * P < 0.01 compared to iron content in non-
targeted group at 1 week after inhalation. 
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Inhalation delivery resulted in a homogenous distribution of SPIO nanoparticles 
throughout the lung (Figure 4.9). One week after inhalation, a significantly higher 
amount of Prussian blue staining was observed in the mice that received targeted particles 
compared to those that received non-targeted particles (Figure 4.8). In the former, the 
staining was observed in and around tumor cells, with near complete absence of particles 
from the healthy parts of the lung. In contrast, the latter group did not display much 
staining in either the tumor or the healthy regions of the lung (not shown). 
 
 
Figure 4.8 Prussian blue staining of lung tumor section after SPIO nanoparticle 
inhalation. One week after inhalation of (A) targeted or (B) non-targeted SPIO 
nanoparticles, mice were euthanized, lung collected, sectioned and stained with 
Prussian blue. Prussian blue binds with free iron to form a blue colored complex. The 
sections (100X magnification) show the presence of lung tumor nodules (red ovals) 
and SPIO nanoparticles in the tumor in EGFR targeted group.  
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4.3.4. Biodistribution of SPIO nanoparticles after high dose instillation 
into lungs 
To study the effect of elevated lung dose of SPIO nanoparticles on the overall 
body distribution, we used tracheal instillation. Unlike inhalation delivery, which restricts 
the dose deposited in mouse lungs to 72.5 ± 14.1 µg of magnetite, tracheal instillation 
allows for a higher dose (386 ± 95 µg of magnetite) to be delivered.  
Following instillation, SPIO particles were mostly observed in the lungs after 1 
hour, although some particles were also present in the stomach, due to the mucociliary 
clearance from the lung. There was no significant difference between the levels of 
targeted and non-targeted particles in the different organs 1 hour or 1 day after 
instillation. The concentration of both particles in blood and other organs (except lung) 
decreased 1 week after instillation compared to 1 hour or 1 day time points (Figure 4.10). 
On the contrary, while the lung concentration of non-targeted particles decreased over the 
period of 1 week, the level of targeted particles was fairly constant over 1 week. The final 
concentration of targeted particles was significantly higher (60%) than non-targeted 
particles one-week post instillation (Figure 4.11). In contrast to the high lung 
Figure 4.9 Distribution of SPIO nanoparticle in mouse lung after inhalation. One 
hour after inhalation of SPIO nanoparticles, animals were euthanized, lung collected, 
sectioned and stained with Prussian blue. Due to the difficulty in visualizing the 
Prussian blue staining in the top picture of the entire mouse lung, an image processing 
software (Image Pro Plus) was used to pseudo-color the Prussian blue stain white 
against a black background (bottom). The pseudo-color image demonstrates the 
homogenous distribution of SPIO nanoparticles post inhalation.   
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concentration, the amount iron in the other tissues was virtually unchanged throughout 
the duration of the study and was not significantly different from the basal level of iron in 
the tissues of untreated animals (not shown). Overall lung concentration of SPIO 
nanoparticles, 1 week post-instillation, was significantly higher than any other tissue 
(Figure 4.12). This data suggested that pulmonary delivery of targeted SPIO 
nanoparticles can circumvent non-specific distribution into organs such as liver and 
spleen, which commonly receive the highest dose of intravenously administered 
therapeutics 239. 
 
 
Figure 4.10 Iron content in tissues at different duration after SPIO nanoparticle 
instillation. Iron content in (A) blood and (B) liver after 1 hour, 1 day or 1 week after 
instillation of targeted or non-targeted SPIO nanoparticles. Iron concentration 
remained steady atleast till a day after instillation and decreased after a week. There 
was no significant effect of targeting on the iron levels in blood and liver. n = 4.  
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Figure 4.11 Iron content in the lungs at different duration after SPIO nanoparticle 
instillation. Iron content in lungs after 1 hour, 1 day or 1 week after instillation of 
targeted or non-targeted SPIO nanoparticles. EGFR targeting enhanced lung retention 
of SPIO nanoparticles over a week. n = 4. * P < 0.05 
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While both instillation and inhalation resulted in a significant increase in lung 
concentration of particles with EGFR targeting, the absolute amount of SPIO particles in 
the two cases were different. The lung iron content after instillation was 4.5 to 5-fold 
higher than that after inhalation (400 vs 80 µg for EGFR-targeted SPIO nanoparticles, 
Figure 4.7 and 4.11). This is likely due to the higher dose of particles delivered to the 
lung through instillation. However, aerosol delivery is a more convenient route of 
administration in humans than instillation. Additionally, inhalation resulted in a more 
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Figure 4.12 Distribution of SPIO nanoparticles 1 week post-instillation. Iron content 
in lungs, heart, spleen, kidneys, liver, stomach and blood are shown as a percent of 
instilled dose. Overall levels of iron in the organs were low except for the lungs. 
EGFR targeting enhanced lung retention of SPIO nanoparticles over a week. n = 4.  
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even distribution of the SPIO nanoparticles throughout the lungs at the time of 
administration (Figure 4.9) compared to instillation (Figure 4.13), where most of the 
instilled dose resided near the major airways, with almost no particles reaching the 
periphery.  
 
 
4.3.5. In vivo efficacy after inhalation 
Magnetic hyperthermia using non-targeted SPIO particles resulted in an 
insignificant decrease in lung tumor bioluminescence (p > 0.05) relative to that in animals 
Figure 4.13 Distribution of SPIO nanoparticles in mouse lung after instillation. One 
hour after instillation of SPIO nanoparticles, animals were euthanized, lung collected, 
sectioned and stained with Prussian blue. Left figure shows the Prussian blue stained 
section of the entire lung and the right figure is a pseudo-color image of the Prussian 
blue stain (white) against a black background (right). The particles are deposited 
primarily along the major airways and the peripheral regions of the lungs are almost 
entirely devoid of SPIO staining.   
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that received the same particles but were not exposed to AMF. Targeted SPIO 
nanoparticles mediated hyperthermia showed significantly lower lung tumor 
bioluminescence (p < 0.05) (Figure 4.14). The lung weights at the end of the study agreed 
with the bioluminescence data; magnetic hyperthermia with targeted particles resulted in 
a significantly lower final lung weight compared to the other groups (Figure 4.15).  
 
 
Figure 4.14 In vivo efficacy of targeted magnetic hyperthermia in an orthotopic lung 
tumor model. Orthotopic lung tumor bearing mice were allowed to inhale targeted or 
non-targeted SPIO nanoparticles. After 1 week, 6 animals from each group were 
subjected to magnetic hyperthermia (MH) for 30 minutes. Lung tumor 
bioluminescence was monitored over a period of 1 month. Data shown = mean ± SD. 
n = 6. * P < 0.05   
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These in vivo results thus confirm that EGFR targeting enhances the tumor 
concentration of SPIO nanoparticles, which translated into more effective tumor cell kill. 
In addition, the treated mice showed no signs of distress over the duration of the study 
(30 days after magnetic hyperthermia treatment), suggesting that this procedure does not 
result in acute systemic toxicity or damage to healthy lung tissue. Additionally, the dose 
of particles that could be delivered to the tumor by inhalation was limited by the small 
lung volume and the obligate nose-breathing of mice 240. A similar approach can be 
Figure 4.15 Lung weight at the end of efficacy study (Figure 4.14). Lungs were 
collected at the end of the efficacy study (1 month after magnetic hyperthermia) and 
weighed. Data shown = Mean ± SD. n = 6. P < 0.05 compared to unheated control. 
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expected to be more effective in humans, because a higher deposition can be achieved 
with inhalation through the oral cavity and control of the respiration.  
 
4.4. Discussion 
Magnetic hyperthermia, which involves the use of superparamagnetic substances 
to generate heat through application of an external AMF, is a non-invasive approach for 
lung tumor ablation. The relatively inert nature of the magnetic substances in the absence 
of magnetic field and their efficacy in the presence of AMF makes this technique highly 
suitable for achieving an on-demand response. Magnetic hyperthermia is particularly 
suitable for the treatment of lung cancer since unlike the abdomen, the thoracic region, 
where the external AMF can be easily focused, is only inhabited by the lungs and the 
heart. Additionally, lungs are filled with air, which act as a poor conductor of heat. Thus, 
the heat generated by the particles in the lungs is less likely to affect the surrounding 
organs such as the heart. Finally, studies have shown that normal, non-malignant cells are 
more resilient to heat damage than tumor cells 241, thereby minimizing the chances of 
damage to healthy lung tissue. Recent reports have suggested that magnetic hyperthermia 
is effective in murine subcutaneous lung tumor models 242,243. However, in spite of the 
promise of a highly effective treatment option, no studies have so far assessed the 
effectiveness of magnetic hyperthermia in an orthotopic lung tumor model. 
Although the lung is a highly perfused organ, intravenous delivery of anticancer 
therapeutics targeted to the lung results in broad, non-specific distribution of the 
therapeutic agents to normal organs, resulting in severe systemic side effects 244. While 
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many solid tumors are not amenable to local delivery, lung tumors of the epithelial origin 
can potentially be accessed by inhalation route. This allows for maximizing the 
concentration of the therapeutic agent in the target organ, i.e., the lungs, while 
minimizing exposure to other normal organs. Lung clearance of particulates into systemic 
circulation is primarily attributed to the alveolar macrophages, which leads to a lower 
blood concentration of the therapeutics than through intravenous administration. Several 
reports have shown that pulmonary delivery improves retention of therapeutic agents in 
the lungs while limiting their concentration in the blood thereby reducing their levels in 
the healthy organs 239,245. Our studies show that lung delivery through either instillation or 
inhalation results in therapeutically effective concentrations of SPIO nanoparticles in 
lungs with minimal exposure to other organs. An hour after instillation of SPIO 
nanoparticles, the average lung concentration of iron oxide was 1.2 mg/g of tissue. In 
contrast, the average liver and blood concentration were 130 µg/g and 27 µg/g of tissue, 
respectively. The other organs including spleen, kidney and heart contained less than 2% 
of the instilled dose. This demonstrates that inhalation delivery is an effective means to 
enhance local concentration of therapeutics into the lungs.  
Following inhalation delivery, it is expected that nanoparticles would be 
distributed to both the malignant and healthy regions of the lungs. The presence of 
targeting ligand on the surface is expected to enable nanoparticles to bind to the tumor 
cells, allowing for greater retention in the tumor tissue. Thus, greater retention within the 
tumor tissue and clearance from normal tissue is expected to eventually result in 
relatively higher levels of nanoparticles in the tumor. Application of AMF during this 
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window would allow for tumor-specific induction of hyperthermia. In our studies, tumor 
cell specificity was achieved by targeting SPIO nanoparticles to EGFR, which is 
overexpressed in NSCLC tumors 140-142. Monoclonal antibodies against EGFR 
(cetuximab) and EGFR tyrosine kinase inhibitors are clinically used for lung cancer. 
Thus, EGFR is an attractive target in lung cancer. We used a previously reported 11-
residue peptide ligand for targeting EGFR 246. This peptide binds specifically and 
efficiently to EGFR (dissociation constant of ~20 nM), but has much lower mitogenic 
activity than EGF 143. We found that EGFR targeting enhanced the in vitro accumulation 
of targeted SPIO nanoparticles into A549 cells by 450% compared to non-targeted 
particles. Aerosolized SPIO particles were directed to the periphery of the lung by 
controlling the aerodynamic size of SPIO aggregates. One hour after inhalation, the 
amount of the targeted or non-targeted particles was similar in tumor-bearing or healthy 
lungs (about 70 µg iron oxide). However, following muco-ciliary clearance from the lung 
(1 week after inhalation delivery), the level of non-targeted SPIO nanoparticles was 
significantly lower than that of targeted particles. This difference could be attributed to 
the presence of tumor targeting ligand on the surface. Thus, by combining receptor 
targeting with inhalation delivery, superior tumor selectivity can be achieved.   
 There are several challenges in the design of an effective inhalation system, which 
can deposit a high dose to the peripheral regions of the lung. Mice are obligatory nose 
breathers, with a small inhalation volume (~24.5 ml/min). This restricts the rate of 
delivery of therapeutics into the lungs. The dose delivered can, however, be controlled by 
changing the concentration of the aerosol generated (mass of aerosol/ volume of air) and 
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the aerodynamic diameter of the aerosol. An MMAD of 1 µm has been shown to result in 
the highest concentration of the therapeutic agents in all lobes of mouse lungs 122, 
yielding a deposition percent (ratio of mass deposited in the lungs to total mass inhaled) 
of about 10 % 123,124. In our studies, we obtained a deposition of nearly 15 % (Supp fig. ) 
with the 1.1 µm MMAD SPIO nanoparticles. The elevated deposition fraction was 
probably attributed to pre-acclimatization of the mice to the inhalation chambers and the 
prolonged exposure (30 min), which prevented undue stress and uneven breathing pattern 
caused by short aerosol exposures. This fraction is amenable to further enhancement by 
using magnetic deposition 124 or micro-spraying technique 125, which can increase the 
deposition fraction of SPIO nanoparticles by several folds.  
The effectiveness of targeted magnetic hyperthermia was evaluated in an 
orthotopic mouse lung tumor model. Intravenous injection of A549 cells led to the 
development of lung tumors, whose bioluminescence scaled with the size of the tumor. 
Lung tumors could be identified at a bioluminescence level of 1 X 105 photons/second 
and the tumor burden reached 90% of the lung volume at 5 X 108 photons/sec. Using an 
optimized aerosol formulation of targeted SPIO nanoparticles, we could achieve 
therapeutic doses of SPIO nanoparticles in the tumors. A single magnetic hyperthermia 
regimen was effective in reducing the tumor growth rate over a month compared to the 
non-targeted or non-treated control. In addition, the treated mice showed no signs of 
distress over the duration of the study (30 days after magnetic hyperthermia treatment), 
suggesting that this procedure does not result in acute systemic toxicity or damage to 
healthy lung tissue. 
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Due to their epithelial nature, lung tumors fill up the alveolar region and thus, 
most tumors are not exposed to the circulating airways. This poses a challenge to the 
success of the nanoparticle system. In spite of enhanced retention of targeted SPIO 
nanoparticles in the tumor, not all tumor cells possessed particles and therefore would not 
receive magnetic hyperthermia therapy. As a result, the treatment showed a significant 
delay in tumor growth but not complete eradication. However, this problem could 
potentially be addressed by using agents that normalize the tumor extracellular matrix 
and enhance the penetration of nanoparticles into the tumor 247,248. Additionally, SPIO 
nanoparticle mediated magnetic hyperthermia may be highly effective as an adjuvant 
therapy for killing isolated tumors cells left behind after surgical resection of the lung 
tumors. 
 
4.5. Conclusions 
Inhalation delivery of EGFR-targeted SPIO nanoparticles was investigated in this 
study as a potential approach for lung cancer treatment. Our studies show that EGFR 
targeting enhances tumor retention of SPIO nanoparticles while minimizing systemic 
exposure. Tracheal instillation allowed for high doses of SPIO nanoparticles to be 
administered, however, aerosol delivery resulted in better intra-tumoral distribution. 
Magnetic hyperthermia using targeted SPIO nanoparticles resulted in a significant 
inhibition of in vivo tumor growth. Overall this work highlights the potential for 
developing magnetic hyperthermia as an effective anticancer treatment modality for the 
treatment of non-small cell lung cancer. 
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Chapter 5 
SUMMARY 
Poor response rates and survival with current treatments indicates an urgent need 
for the development an effective means to treat NSCLC. In this study, an aerosol-based, 
tumor-targeted SPIO nanoparticles system was used to induce highly selective magnetic 
hyperthermia for the treatment of lung cancer.  
The objective of the first study was to identify the mechanism of cell kill by 
magnetic hyperthermia, with a particular focus on the effect of aggregation state of SPIO 
nanoparticles. Overabundance of salt and protein in biological milieu often favors 
aggregation of inorganic nanoparticles. Studies in Chapter 2 demonstrate that the particle 
size of aggregates affects the therapeutic performance of SPIO nanoparticles. Well-
dispersed SPIO nanoparticles induced apoptosis, similar to that observed with 
conventional hyperthermia. Sub-micron size aggregates (hydrodynamic diameter less 
than 500 nm), on the other hand, induced temperature-dependent autophagy through 
generation of ROS. Micron size aggregates (larger than 1 µm) caused rapid membrane 
damage and acute cell kill even in the absence of temperature elevation, suggesting a 
temperature-independent mechanism of action, likely due to physical motion of the 
aggregates in AMF. Interestingly, solid micron size iron oxide particles did not exhibit 
enhanced acute cell kill in the absence of temperature elevation, thus confirming the 
importance of the smaller superparamagnetic iron oxide cores and the micron size of the 
final aggregate in this process. This novel mechanism of cell kill induced by micro 
aggregates translated into effective in vivo tumor growth inhibition. Overall this work 
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highlighted the potential for developing highly effective anticancer therapeutics through 
simple yet often overlooked modifications of delivery systems such as their state of 
aggregation.  
This is a very important finding especially in the field of magnetic hyperthermia. 
One of the primary limitations of this technique is the necessity of a “sufficient” quantity 
of magnetic particles at the site of action to successfully induce heat-mediated cell death. 
Depending on the heating potential of the magnetic particles used, the quantity required is 
often in the range of a few milligrams per gram (or cm3) of tumor. Studies in Chapter 2 
suggested that for a well-designed SPIO nanoparticle system, the distribution of these 
particles in the tumor, and not their amount, will be more critical for the effectiveness of 
magnetic hyperthermia. 
CSCs are considered to play important roles in tumor drug resistance and 
recurrence. Studies in Chapter 3 evaluated the susceptibility of CSCs to magnetic 
hyperthermia. Our studies showed that CSCs and non-CSCs are equally susceptible to 
cell death induced by a mix of sub-micron and micron sized SPIO aggregate mediated 
magnetic hyperthermia. Further, magnetic hyperthermia induced both acute necrosis and 
a slower, ROS-mediated cell-death in treated cells. Some of the cell kill events appeared 
to be temperature-independent, although elevated temperatures appeared to amplify those 
effects. Overall, the results of this study suggested the potential for effective CSC 
eradication by magnetic hyperthermia.  
This observation is of particular importance for the treatment of lung cancer 
where tumor recurrence is common in the first five years after diagnosis. While systemic 
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chemotherapy is used to treat circulating tumor cells, clinical results and numerous pre –
clinical studies have shown that CSCs are resistant to chemotherapy. Thus, treatment 
options that completely eradicate the tumors including the CSCs can potentially decrease 
the risk of tumor recurrence. Studies in Chapter 3 demonstrate, through numerous in vitro 
and in vivo CSC assays, that magnetic hyperthermia can affect these cells in manifold 
ways. However, future studies need to be performed to investigate the effect of magnetic 
hyperthermia on in vivo tumor growth and tumor recurrence. 
Inhalation delivery of EGFR-targeted SPIO nanoparticles was investigated, in the 
final study, as a potential approach for lung cancer treatment. Studies in Chapter 4 
demonstrate that EGFR targeting enhances tumor retention of SPIO nanoparticles while 
minimizing systemic exposure. About 50 – 60% higher lung concentration of targeted 
SPIO nanoparticles was seen after different routes of lung delivery – tracheal instillation 
and inhalation. Tracheal instillation allowed for high doses of SPIO nanoparticles to be 
administered, while aerosol delivery resulted in better intra-tumoral distribution. 
Magnetic hyperthermia using inhaled targeted SPIO nanoparticles resulted in a 
significant inhibition of in vivo tumor growth.  
Though these results are highly encouraging, it must be noted that the tumor 
progression was slower but not completely inhibited. One of the factors responsible for 
this incomplete response is the nature of lung tumor formation. Due to their epithelial 
nature, lung tumors fill up the alveolar region and thus, most tumors are not exposed to 
the circulating airways. Thus, inspite of enhanced retention of targeted SPIO 
nanoparticles, not all tumor cells had particles in them and therefore did not receive 
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magnetic hyperthermia therapy. A potential solution for this problem is co-administration 
agents that normalize the tumor extracellular matrix and enhance the penetration of 
nanoparticles into the tumor.  
Another prospective application of SPIO nanoparticle mediated magnetic 
hyperthermia is as an adjuvant therapy for killing isolated tumors cells left behind after 
surgical resection of the lung tumors. While larger tumor nodules can be surgically 
removed, isolated cells often remain undetected by current imaging techniques. Due to 
their smaller dimensions, they are unlikely to occlude the whole alveolar space and can 
therefore be treated with inhaled targeted SPIO nanoparticle mediated magnetic 
hyperthermia.  
Overall, this work highlights the potential for developing magnetic hyperthermia 
as an effective anticancer treatment modality for the treatment of NSCLC.  
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